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ABSTRACT 
Inhalation represents a potentially attractive delivery route for biologics, 
especially those designed to treat pulmonary diseases such as asthma, 
cystic fibrosis or lung cancer. Delivery directly to the site of action 
should increase local concentrations of drug, whilst reducing systemic 
side effects. However, there is limited knowledge regarding the 
mechanisms of pulmonary clearance, with gaps in understanding; 
where molecules are absorbed, the mechanisms involved, regional 
variability throughout the lung, and how to control pulmonary retention 
and/or facilitate cellular uptake. 
The work presented in this thesis details the development of a 
SPECT/CT imaging protocol to determine the pulmonary retention and 
tissue redistribution of technetium labelled antibodies and their 
fragments in vivo, in mice, to begin to address these knowledge gaps. 
The SPECT/CT imaging method was applied to a whole monoclonal 
murine immunoglobulin G1 (mlgG1), as well as its Fab and scFv 
fragments and a small protein (FN3) in order to determine whether 
diffusion controlled pathways were important in pulmonary antibody 
clearance. Additionally, the pulmonary retention of mutant mlgG1 with 
differing binding affinities to the murine neonatal Fc receptor (mFcRn) 
were assessed in order to determine whether antibody transport across 
the epithelium occurred via active transcytosis. 
It was determined that 54.4 ± 0.63 % of the total instilled dose of a 
whole monoclonal antibody remains in the lung over 24 hrs, with Fab 
and scFv fragments cleared significantly quicker with 28.7 ± 0.73 % 
and 34.9 ± 0.85 % respectively of the total instilled dose remaining in 
the lung at 24hrs. The pulmonary retention of the 11 kOa FN3 protein 
was also assessed with 21.0 ± 0.65 % remaining in the lungs after 24 
hrs. No evidence of build up of any protein was detected in the 
oesophagus/stomach, suggesting little contribution by mucociliary 
clearance. Very little build up of whole antibody, Fab or scFv was 
observed in the liver or kidneys. However, very clear evidence of renal 
filtration of the 11 kOa fragment was observed. There was no 
difference in the pulmonary retention of wild type IgG and any of the 
mFcRn binding mutants. 
Additional investigation of antibody retention rates in the murine house 
dustmite (HOM) model of asthma, although not making use of the 
SPECT/CT method, showed that antibody is cleared more rapidly from 
the diseased lung than the normal lung. It was also shown that the 
expression pattern of the mFcRn receptor is the same in the normal 
and HDM exposed lung and so this increase in clearance rate occurs 
via passive diffusion controlled processes. This is most likely a result of 
ii 
increased paracellular transport due to disrupted mucosal barrier 
function. 
The SPECT/CT imaging method developed has proven to be a simple 
and reliable method to assess, non-invasively, pulmonary antibody 
retention in vivo. Overall it appears that antibody transport across the 
pulmonary epithelium occurs predominantly via diffusion controlled 
mechanisms, which include both paracellular transport and non-
specific transcytosis by pinocytotic routes. Additionally, in the mouse, 
neither receptor mediated transport by mFcRn nor mucocillary 
clearance is important in the pulmonary clearance of antibodies. 
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CHAPTER 1: General Introduction and Literature 
Review 
1. Project Overview 
The overall aim of the work detailed in this thesis was to investigate 
inhalation as a potential delivery route for therapeutic antibodies. It is 
hoped that exploitation of currently unused delivery routes for biologics 
will lead to an increased number of therapies reaching the market, 
herping to reduce unmet patient need. 
1.1 Delivery of Biologics 
Research into the development of biologic based drugs such as 
monoclonal antibodies, recombinant proteins and growth factors is a 
rapidly expanding sector of the pharmaceutical industry. The first 
biologic drug approved for delivery to patients was recombinant human 
insulin in 1982, with the first monoclonal antibody, muromonab, FDA 
approved in 1986 (Reichert, et aI., 2005). Since then the FDA has 
approved over 130 biological based drugs and as of May 2011 there 
are 26 monoclonal antibody therapies approved for delivery to patients 
in the USA. (Reichert, 2012) 
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Protein based therapies, such as monoclonal antibodies, are generally 
high molecular weight, hydrophilic and rapidly denatured in the 
gastrointestinal tract. These factors make oral formulation of biologics 
difficult and result in poor oral bioavailabilities for the vast majority of 
biologic based therapies (Antosova, et aI., 2009). Consequently 
parenteral delivery is the most common delivery route for biologics, 
with numerous formulations available on the market formulated for 
subcutaneous, intravenous or intramuscular injection. 
Parenteral delivery avoids denaturation of the therapeutic protein in the 
gastrointestinal tract and provides rapid systemic delivery with 
bidavailabilities approaching 100%. However, there are drawbacks to 
parental delivery including patient discomfort, high cost of goods; 
related to the strict asepsis required in the final formulation and poor 
safety of parenteral delivery in countries which lack reliable access to 
sterile needles and syringes (Chames, et aI., 2009). 
Intravenous dosing of antibodies, for example Herceptin© 
(trastuzumab) and Avastin© (bevacizumab), generally involves 
infusion, which necessitates that therapy is provided in a clinical setting 
by a trained medical professional. Intramuscular or subcutaneous 
injection is less time consuming and inconvenient for patients than 
intravenous dosing. Humira© (adalimumab) an anti-TN Fa monoclonal 
antibody used to treat rheumatoid arthritis is a monoclonal antibody 
that is currently FDA approved for subcutaneous injection (Eisenstein, 
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2011) and a subcutaneous formulation of Herceptin© currently in 
phase III clinical trials. (Eisenstein, 2011). 
One biologic, Xolair© is currently marketed for the treatment of asthma. 
Figure 1.1 lists a selection of biologics currently in clinical trials for 
asthma, capo or pulmonary fibrosis treatment. 
Biologic Description Disease Status 
Omalizumab(1 ) Anti-lgE antibody Asthma Approved 
Mepolizumab(1) Anti-IL5 antibody Asthma Phase 111111 
Tralokinumab(1) Anti-IL 13 antibody Asthma Phase II 
MEOI-528 (1) Anti-IL-9 antibody Asthma Phase II 
STX-100 (2) Anti-avJ36 Integrin Pulmonary Fibrosis Phase II 
} antibody 
CNT0888 (2) Anti-CCL2 antibody Pulmonary Fibrosis Phase II 
QAX576 (2) Anti-IL 13 antibody Pulmonary Fibrosis Phase II 
Etanercept (3) Anti-TNFa fusion protein COPO Phase II 
ACZ-885 (4) IL-1 J3 agonist CO PO Phase II 
S8-681323 (4) P38 MAPK inhibitor COPO Phase II 
Figure 1.1 - Table summarising biologics currently marketed or in clinical trials 
for pulmonary disease. Data from (1) Pelaia, et a!. 2012 (2) Rafii, et al. 2013 (3) 
Aaron, et al. 2013 (4) Morjaria, et al. 2012. 
1.2 .Research into non-invasive delivery of biologics 
There has been a significant level of research into the development of 
non-invasive protein delivery systems, including nasal, buccal, 
transdermal, pulmonary and oral delivery (Brown, 2005). The most well 
known example of a non-invasively formulated biologic is the 
pulmonary delivery of insulin for the treatment of diabetes. The 
3 
development of inhaled insulin formulations was a very active area of 
research until the withdrawal of Pfizer's FDA approved inhaled insulin 
product Exubera© from the market in 2008, citing poor sales. Other 
inhaled insulin projects in late phase clinical trials, such as the Novo 
Nordisk AERx1 formulation (insulin Diabetes Management System, 
iDMS), were then stopped due to the perceived lack of commercial 
potential (Bailey & Barnett, 2007). 
There is a small number of biologics currently marketed in non-invasive 
formulations, these include: Miacalin© a nasal formulation of the 
polypeptide hormone calcitonin from Novartis to treat postmenopausal 
I 
osteoporosis and Minirin© an oral formulation of demopressin (a 
synthetic form of antidiuretic hormone) from Ferring that is used to treat 
nocturnal enuresis (Moeller & Jorgensen, 2008). In terms of pulmonary 
delivery the most successful biologic based drug currently on the 
market is Pulmozyme© a recombinant human DNAse delivered by 
nebulisation to relieve the symptoms of cystic fibrosis. There are also 
numerous inhaled biologic projects currently in late stage 
development/early clinical trials, for example Ablynx is currently 
running a Phase 1 trial to test the safety of an inhaled nano-body 
based drug to treat respiratory syncytial viral infections (Schepens, et 
aI., 2011). 
Pulmonary delivery of antibody formulations could be achieved using 
nebulisation for liquid based formulations or dry powder inhalers for 
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solid formulations. A significant amount of research has been 
undertaken to allow the formulation of proteins, including therapeutic 
antibodies, for both nebulisation and in inhalers. 
In terms of the suitability of nebulisation for antibody delivery to the 
lung, a study by Mailet (Maillet, et aI., 2008) investigated Cetuximab, a 
monoclonal antibody against EGFR with approval for use in the 
treatment of metastatic cancer. It was demonstrated that the antibody 
was both resistant to formulation for nebulisation and able to retain 
functionality following nebulisation. 
, 
In terms of antibody formulation for dry powder inhalation, numerous 
studies have determined suitable excipients to promote the successful 
freeze or spray drying of the protein. The major challenges in 
producing a suitable dry powder antibody formulation are maintenance 
of protein stability, minimising aggregation, glycation and lactosylation 
(Constantino, et aI., 1998). Additionally, excipients are required to tailor 
the bulk flow properties of the powder formulation so that a suitable 
aerosol can be formed for delivery to the lung. In general antibody 
stability is improved with the addition of carbohydrate excipients such 
as mannitol and lactose (Constantino, et aI., 1998b) which, provided 
that the protein to excipient ratio is optimised, are also capable of 
producing formulations which are amenable to aerosolisation (J 0 
Andya, et aI., 1999). 
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1.3 The lung 
There are numerous reasons to believe that inhalation is an attractive 
delivery route for biologics, generally due to the large, highly perfused 
surface area for absorption within the lung. Pulmonary delivery is also 
commonly utilised for small molecules, particularly in the delivery of 
glucocorticosteroids and bronchodilators in the maintenance and 
treatment of asthma. Additionally, the antibiotic tobramycin is 
formulated as an aqueous nebulization for the treatment of 
"Pseudomonas" infections in cystic fibrosis patients. 
I 
Additionally, delivery of biologics to treat lung disease, for example in 
lung cancer, cystic fibrosis or asthma, is also possible and in such 
cases it is anticipated that delivery direct to the site of action would 
reduce systemic side effects and increase local drug concentrations 
when compared to parenteral delivery routes. 
1.3.1 Structure of the human lung 
The primary functions of the lungs are to deliver oxygen to the 
bloodstream and remove carbon dioxide from the body. In general the 
lung is split into two anatomical regions, the conducting regions which 
transmit air through the lungs and the respiratory regions where gas 
exchange occurs. The structure of the human lung, from the trachea to 
the alveoli, is shown in Figure 1.2 
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Figl,Jre 1.2 - Image depicting the structure ofthe lung, from the trachea to the 
alveolar sacs, showing the branching nature of the airways. Picture from 
(Patton & Byron, 2007) 
The conducting regions of the lung consist of the trachea, bronchi and 
bronchioles. The trachea is the largest conducting airway, with an 
average diameter of 2-2.5 cm in humans and which divides into two 
smaller bronchi after an approximate length of 9 - 12 cm. Each of 
these bronchi then further branches into two smaller bronchi as shown 
in FigUre 1.2 and this pattern of bifurcation repeats 15 times until the 
first level of the respiratory regions of the lung is reached (Weibeland & 
Gomez, 1962). The diameter and length of the bronchi decrease with 
each progressive bifurcation, until the terminal respiratory bronchioles, 
at 0.5 mm in diameter, further divide into the alveolar ducts and sacs, 
which are the main site of gas exchange within the lungs (Itoh, et aI., 
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2004) and which cover an approximate area of 100 m2 (Owens, et aI. , 
2003). It is clear from this description of the anatomy of the lung that 
the surface of the lung is not homogeneous, with for example the 
alveolar epithelium being significantly different to the tracheal 
epithelium. 
1.3.2 Pulmonary epithelium 
The epithelium in the trachea is classified as pseudostratified columnar 
epithelium and is ciliated. Figure 1.3 shows a representation of the 
tracheal epithelium. 
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Figure 1.3 - Images showing the structures of the tracheal, small bronchial and 
alveolar epithelia, from (Patton & Byron, 2007) 
There are 3 major cells types present, ciliated cells, basal cells and 
goblet cells. The ciliated cells extend from the basal lamina to the 
8 
luminal surface, forming tight junctions with each other. There are 
between 200-300 cilia on the surface of each ciliated cell, which are 
0.25 ~ m m in diameter and 6 ~ m m in length (Proud, 2008). Basal cells 
attach to the basement membrane and support the ciliated cells. 
Goblet cells secrete the mucins which form part of the mucus layer 
which covers the epithelium. The mucus layer in the trachea and 
largest airways is around 8 ~ m m deep and functions to trap inhaled 
particulates such as dust and allow for their removal from the lungs 
(Patton, 1996). The mucus layer is in fact made up from two distinct 
layers, a highly viscous gel layer lying on top of a less viscous sol 
layer. The more viscous top layer traps inhaled particulates whereas 
the less viscous bottom layer facilitates effective beating of the cilia. 
The cilia beat to move the mucus layer, on the upward beat the cilia 
are fully extended into the gel layer and push the mucus up the 
trachea, on the downbeat the cilia contract into the sol layer, before 
extending again into the gel layer for the next upbeat. In this way the 
gel layer is moved continually up the trachea to the mouth, where the 
mucus and any inhaled particulates trapped in it are swallowed 
(Lenaerts & Gurny, 1990). 
The larger bronchi possess an epithelium that is very similar to the 
trachea, however, as the bronchi become progressively shorter and 
smaller in diameter the nature of the epithelium changes with less 
ciliated cells present and a gradual transition to a thinner, more 
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squamous, organisation. This changing epithelium is represented in 
Figure 1.3. 
The alveolar epithelium (again represented in Figure 1.3) is 0.1 - 0.4 
IJm thick and made up of two cell types. The large flat squamous Type I 
cells cover 90 % of the alveoli surface with the remaining 10 % covered 
with cuboidal Type II cells which secrete the alveoli lining fluid, which is 
70 nm in depth (Crapo, et aI., 1983). Tight junctions are formed 
between neighbouring cells. The alveol are suited to gas exchange 
primarily due to the very short diffusion path between the airspaces 
and bloodstream. The partial pressure of oxygen is also higher in the 
alveolar regions than the bloodstream, with the opposite true for the 
partial pressure of carbon dioxide. This provides a gradient to drive 
oxygen incorporation into the blood and carbon dioxide removal from 
the blood (Smyth & Hickey, 2011). 
1.3.3 Tight junctions 
All sections of the airways from the trachea to the alveolar sacs are 
characterised by epithelial barriers where cells are joined by tight 
junctions. Tight junctions provide points of contact between adjacent 
cells and are located just below the apical surface. The junction is 
composed of predominantly claudin and occulin protein strands which 
are anchored to the cytosketeton, extend through the cell membrane 
and directly interact with the extracellular domains of protein strands 
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extending from neighbouring cells (Tsukita & Itoh, 2001) (Martin-
Padura, et aI., 1998) (Furuse, et aI., 1993). The structure of the tight 
junction is shown in Figure 1.4. 
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Figure 1.4 - Images showing the structure of the tight junction in the pulmonary 
epithelium. 
The junctions function to structurally link adjacent cells, providing a 
barrier to the free diffusion of molecules between the epithelial cells 
(Chen-Quay, et aI., 2009). This allows the epithelium to function 
correctly as a barrier and prevents any excessive build-up of fluid in the 
lungs. The junctions are selectively permeable, regulating the passage 
of water, ions and other solutes (Rubas, et aI., 1996) and are 
considered to result in a paracellular space of between 0.1 and 5 nm 
(Madara, 1998). 
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In terms of the pulmonary delivery of biologics, tight junctions will 
prevent the free diffusion of any inhaled product between the cells of 
the pulmonary epithelium and as such the rate of paracellular transport 
of larger biologics is expected to be very slow. 
1.4 Pulmonary delivery of biologics 
The initial distribution of an inhaled biologic within the lung is largely 
determined by the delivery device, (Patil & Sarasija, 2012) and is 
generally concerned with tailoring particle/droplet size to preferentially 
deposit the dose in the trachea (larger particles), conducting airways or 
lower airways/alveoli (smaller particles) (Isaacs, et aI., 2004), 
(Borgstron, et aI., 2006). However, once the formulation has been 
deposited within the lung little is known about the mechanisms by 
which it redistributes within the lung tissue and how ultimately it is 
transported out of the lung. Our understanding of the pulmonary 
distribution of inhaled biologics is further complicated by different local 
permeability and clearance mechanisms in the alveolar vs. bronchial 
regions. 
Any biologic deposited in the trachea will initially make contact with the 
mucus layer, a sol-gel layer which is moved slowly towards the larynx 
by the beating of the cilia on the surface of the underlying epithelial 
cells (Cuand & Saltzmann, 2009). An inhaled biological must be able to 
diffuse through the mucus layer before it is moved up the trachea to the 
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larynx and swallowed, or the biologic will not successfully reach the 
lung. The factors which influence diffusion through the mucus layer 
include the size of inhaled molecule and any interaction between the 
inhaled molecule and the components of mucus (Khanvilkar, et aI., 
2001) (Thornton & Sheehan, 2004). It has been demonstrated that 
neutrally charged particles are more easily able to diffuse in the mucus 
and reach the underlying epithelium, whereas charged particles 
interact more strongly with mucus and diffuse more slowly (Weers, et 
aI., 2010). A study by (Saltzmann, et aI., 1994) found that antibody 
transport through cervical mucus was rapid, with the diffusion in mucus 
comparable to that in water. As such, diffusion through the mucus layer 
is not anticipated to be the rate limiting step in pulmonary antibody 
clearance. 
A biologic deposited in the alveoli will initially make contact with the 
alveolar lining fluid. In contrast to the trachea, there is no mucus layer 
to diffuse through and the alveolar lining fluid layer is particularly thin. 
However, the alveoli have two defence mechanisms which are not 
present in the trachea/upper airways, which can greatly influence the 
amount of an inhaled drug which is able to reach the pulmonary 
epithelium. First the lining fluid contains proteases which will quickly 
degrade inhaled peptides, although larger proteins such as IgG are 
degraded much more slowly and can persist in the lung for several 
days (Byron & Patton, 1994). Secondly, alveoli are patrolled by 
macrophages with the human lung estimated to contain around 500 
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million alveolar macrophages, with approximately 12-14 macrophages 
per alveolus (Chrystal, et aI., 1997). Any inhaled biologic will be 
phagocytosed if it does not quickly dissolve in the alveolar lining fluid. 
Strategies such as containing inhaled drugs in polymer nano- or micro-
particles have been shown to be able to reduce their susceptibility to 
macrophage clearance (Jones, et aI., 2002). Additionally, the 
PE'Gylation of such encapsulated formulations has been suggested as 
a route to both avoid macrophage detection and promote pulmonary 
retention. PEGylated micro-particles have been shown to be retained in 
the lung longer than unmodified microparticles, although it is not clear 
where exactly within the lungs the particles were located (Kutscher, et 
al.,2010). 
Once an inhaled biologic diffuses through the fluid lining the lung and 
reaches either the bronchial or alveolar epithelial cells even less is 
known about how biological molecules are internalised or transported 
out of the lung. 
1.5 Crossing pulmonary epithelium 
In general there are two main pathways by which an inhaled biologic 
could cross the pulmonary epithelium. Firstly by paracellular transport, 
that is transport by diffusion between the epithelial cells. Secondly by 
transcytosis, that is transport through the epithelial cells. This transport 
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through the epithelial cells can be subdivided into two different 
pathways, active and passive transport. Passive transport is non-
specific transport through the cell and active transport is the selective 
uptake and delivery of a molecule through the cell by a dedicated 
receptor. The neonatal Fc receptor (FcRn) is known to bind and 
transport IgG and has been shown to be capable of actively 
transporting IgG though pulmonary epithelial cells (Roopenian & 
Akilesh, 2007). The three different transport routes across the 
pulmonary epithelium are represented pictorially in Figure 1.5 
Paraeellular Diffusion 
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Airway 
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Figure 1.5 - A diagram showing the possible pathways for IgG to cross the 
pulmonary epithelium and enter the systemic circulation. In paracellular 
diffusion (blue arrow) the IgG would pass between the epithelial cells through 
t ~ e e tight junctions. In transcytosis the IgG would pass through the epithelial 
cells, either non-specifically (green arrow), or via binding to the FcRn receptor 
(purple arrow). 
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1.5.1 Paracellular transport 
Paracellular diffusion is non-specific and is diffusion controlled. 
Diffusion is governed by Fick's Law, which defines the movement of a 
substance (J) as being directly proportional to the concentration 
gradient (::), according to the following equation: 
a 
l(x, t) = -D ax c(x, t) 
Where: 
J = Flux or the amount of substance moving though a defined area 
over a defined time (e.g. mol/cm2/s) 
x = defined unit a-rea (e.g. cm2) 
t = defined unit time (e.g. s) 
D = Diffusion constant 
:x c = concentration gradient (change in concentration over a defined 
unit area) 
The magnitude of the diffusion constant (D) is related to both the size 
of a given substance and the properties of the medium that it is 
diffusing in. Figure 1.5 relates molecular weight and D for a variety of 
substances in water. 
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The data in Figure 1.6 show that the magnitude of D is inversely 
related to molecular weight, in a given diffusion medium, meaning that 
larger molecules have smaller diffusion constants. Using the equation 
for Fick's Law, a smaller diffusion constant always results in a lower 
rate of diffusion, indicating that molecular weight is inversely related to 
the rate of diffusion. In terms of paracellular transport between cells 
this relationship indicates that smaller molecules ought to pass more 
quickly between the cells in the pulmonary epithelium than larger 
molecules. 
Substance Molecular weight (Oa) o (x107 cm2/s) 
Glucose 192 660 
Insulin 5734 210 
Cytochrome c 13370 11.4 
Serum albumin 68500 6.1 
Catalase 247500 4.1 
Fibrinogen 339700 2.0 
Figure 1:6 - Table showing relationship between Diffusion constant 0 and 
molecular weight of a series of common biological species in water. Data from: 
(Fall, et al., 2005) 
IgG is very large at 150 kDa and as such would be expected to slowly 
diffuse out of the lung. The results of various studies into transport of 
proteins/peptides out of the rat lung are shown in Figure 1.7 with the 
time taken to reach maximum concentration in the plasma (Tmax) 
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compared to the molecular weight of the protein. The graph shows a 
correlation between molecular weight and Tmax, with smaller peptides 
more quickly transferred out of the lung and into the blood than larger 
proteins such as albumin and IgG. 
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Figure 1.7 - A summary of available data for the in vivo pulmonary clearance of 
proteins 'after inhalation in rats, expressed as the time to reach maximum 
concentration in the blood vs. the molecular weight of the protein (data from: 
(Byron & Patton, 1994». 
There are many other factors than simple molecular weight which could 
influence the rate of paracellular transport such as hydrophobicity, 
hydrodynamic radius and overall charge (Patton, 1996). In general the 
smaller and more hydrophilic a molecule, the quicker it has been 
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shown to cross the epithelium (Kobayashi, et aI., 1995) (Effros & 
Mason, 1983) . 
Numerous studies have shown that the effective pore size in the 
pulmonary epithelium is predominantly 1-5 nm (Patton, 1996), with 
molecules having a hydrodynamic radius under 5nm being transported 
rapidly out of the lung (Wangensteen, et aI., 1993). It is thought that 
this represents paracellular transport through the tight junctions, 
although this has never been visualised. 
1.5.2 Non-specific transcvtosis 
Non-specific transcytosis involves the uptake of fluid, and any solutes 
present, into vesicles and their transportation through the cell. This 
process is entirely non-specific and as such all molecules will be 
transported though the pulmonary epithelium in this manner, however 
the likelihood that a molecule will be taken up into the vesicles is 
controlled by diffusion. As for paracellular transport this non-specific 
transcytotic pathway will be related to molecular weight with larger 
molecules being transcytosed more slowly than smaller molecules. In 
actuality, non-specific transcytosis is not a single pathway, with 
numerous possible routes to uptake and transport molecules through 
the cell (Royand & Wrana, 2007) (Mayorand & Pagano, 2005). 
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The simplest non-specific transcytotic route is adsorptive pinocytosis 
where invaginations in the plasma membrane trap a random sample of 
the luminal fluid, which is then transported into the early endosome, 
from where it can be transferred to the degradative lysosomal pathway, 
recycled back to the apical surface or transferred to the basolateral 
surface resulting in transcytosis (Alberts, et aI., 1994). 
Another route for non-specific transcytosis is via uptake into caveolae, 
which are invaginations of the plasma membrane, approximately 50-
100 nm in diameter, which contain proteins from the caveolin family 
and cholesterol (Gumbleton, 2001). As caveolae form, fluid is 
entrapped by pinocytosis, the contents of the caveolae can then either 
be delivered to the endosome or trafficked across the cell, where the 
caveolae fuse with the plasma membrane at the opposite cell surface 
and the cargo is released. There are two proposed mechanisms for the 
transcytotic pathway, either a single caveola crosses from one plasma 
membrane to the other or multiple caveolae fuse, passing the cargo 
across the cell (Gumbleton, et aI., 2003). There is some evidence that 
caveolar transport involves rapid shuttling, which can bypass transfer 
of cargo to the endosome and promote transcytosis (Plant, et aI., 
2012). 
Transcytosis can also occur following endocytosis in vesicles coated in 
clathrin (Pucadyil & Schmid, 2009). The vesicle's transport through the 
cell is mediated by actin, with the vesicle ultimately fusing with the early 
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endosome (Sahay, et aI., 2010a). Clathrin dependent endocytosis is 
specific for certain required nutrients, such as iron via the transferrin 
receptor and cholesterol via attachment to the low density lipoprotein 
(LDL) receptor (Plant, et aI., 2012), however numerous studies have 
shown that the process can transport other cargo, predominantly 
nanoparticles, both into and through the cell (Sahay, et aI., 2010b). 
As the rates of both non-specific transcytosis and paracellular transport 
are diffusion controlled it is difficult to differentiate between these two 
pathways in vivo. However, it should be possible to determine whether 
passive transport by either paracellular transport or non-specific 
transcytosis, is important in pulmonary antibody clearance. 
1.5.3 Receptor mediated transcvtosis 
The neonatal Fc receptor (FcRn) was first identified in rodents as the 
receptor responsible for transferring IgG from mother's milk across the 
neonatal intestine (Brambell, 1970). Later work has identified 
numerous roles for FcRn throughout the body, with FcRn expressed in 
the placenta functioning to transfer IgG from mother to offspring in 
humans (Leach, et aI., 1996). Additionally, FcRn is important in IgG 
homeostasis (Roopenian & Akilesh, 2007), with FcRn knockout mice 
having abnormally low IgG serum levels and increased IgG catabolism 
rates (Roopenian, et aI., 2003) (Ghetie, et aI., 1996) . 
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FcRn expression is common in many tissues including the lung, kidney, 
intestine, liver, eye, at the blood-brain barrier and in antigen presenting 
cells (Kim, et aI., 2008) (Spiekermann, et aI., 2002) (Zhu, et aI., 2001) 
(Roopenian & Akilesh, 2007). Additionally, FcRn expression has been 
confirmed in all mammalian species so far tested (Ward & Ober, 2009). 
There is limited interspecies FcRn cross-reactivity with mouse FcRn 
binding IgG from most species including human, rabbit, bovine, rat and 
., 
sheep (Ober, et aI., 2001). However, human FcRn is far more specific, 
with very poor binding to non human IgG. 
Numerous studies have demonstrated the capacity of FcRn to 
transcytose IgG across polarized epithelial cells (Tzaban, et aI., 2009). 
It is important to note that FcRn is not expressed on the apical cell 
surface, but is located within the endosome. As such transport by FcRn 
does not involve and active uptake of IgG into the cell. However, once 
the IgG reaches the endosome, FcRn facilitates active transport of the 
IgG away from degradative pathways and out of the cell. 
In more detail, the receptor mediated transcytosis of IgG by FcRn 
begins, as for non-specific transcytosis, with plasma membrane 
invagination forming a fluid filled transport vesicle, which contains the 
IgG (Abrahmason & Rodewald, 1981). The vesicle transports the IgG 
to the endosome, where binding of IgG to FcRn occurs at the lowered 
pH of 6.0-6.5 (Praetor, et aI., 1999). The IgG, which is bound to FcRn, 
avoids transfer to the degradative Iysosomes and instead is 
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exocytosed from the cell when its transport vesicles fuse with the 
plasma membrane at the basolateral side of the cell (Deng, et aI. , 
2010). The increase in pH to 7.0-7.5 in the interstitial space causes 
disassociation of IgG from FcRn, with the net result being transport of 
IgG from the epithelial surface fluids to the interstitial space (Datta-
Mannan, et aI., 2007). 
The interaction of IgG to mFcRn has been studied extensively and the 
crystal structure of the FcRn-lgG complex has been solved (Martin, et 
aI., 2001). This enabled key residues, which facilitate the interaction, to 
be identified, these can be seen in Figure 1.8 . 
... ~ . - Ue253 
Figure 1.8 - Location of the key residues on IgG which facilitate binding of IgG 
to FcRn. From: _{Ward & Ober, 2009) 
The binding of human IgG with human FcRn is stabilised by two salt 
bridges, one between IgG Histidine _310 and FcRn Glutamine _117 and 
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the second between IgG Histidine_ 435 and FcRn Glutamine_132. In 
addition there is a strong hydrophobic interaction between IgG 
Isoleucine 253 and FcRn Tryptophan_253 (Ghishan, et aI., 2006). 
Modification of Histidine 310, Histidine 435 or Isoleucine 253 to alanine 
in IgG results in dramatically reduced or completely ablated binding of 
FcRn (DaIl'Acqua, et aI., 2002) (Kabat, et aI., 1991). The same 
residues are conserved in mouse IgG1 and their mutation again results 
, 
in decreased binding to mouse FcRn, additionally mutation of Valine 
250 to Glutamine has been shown to result in increased binding of 
mlgG1 to mFcRn (Raghavan, et aI., 1995) (Dall'Acqua, et aI., 2002). 
The importance of histidine residues in the FcRn-lgG binding 
interaction can help explain the pH dependence involved in IgG 
transcytosis (Roopenian & Akilesh, 2007). In the endosome, where 
binding occurs, the pH is slightly acidic at 6.0 - 6.5. Under these 
conditions histidine residues protonate and permit the salt bridge 
stabilisation of the IgG-FcRn complex. At the neutral pH encountered in 
the interstitium, the histidine residues on IgG re-protonate, removing 
salt bridge stabilisation of the complex and promoting dissociation of 
IgG from the receptor (Vaughn & Bjorkman, 1998). 
In summary, a mechanism exists by which IgG can be actively 
transported across the pulmonary epithelium, therefore the pulmonary 
clearance of IgG should occur at a faster rate than would be expected 
from diffusion controlled pathways alone. However, the relative 
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contributions of both diffusion and transcytosis in terms of IgG crossing 
the pulmonary epithelium are not known. 
1.5.4 FcRn Expression and activity in the lung 
FcRn is expressed in a wide range of tissues and on the majority of cell 
types. There has been some research into the expression of FcRn in 
., 
the lung although the results are contradictory. A study by 
(Spiekermann, et aI., 2002) provides the best evidence for FcRn 
expression within the human and cynomolgus monkey lungs, with 
immunohistochemical staining for FcRn showing expression in the 
bronchial epithelia. There was also evidence of weaker bronchial 
expression of FcRn in mouse lungs. However, another study (Akilesh, 
et aI., 2007) found no evidence of FcRn expression in either the 
bronchial epithelium or endothelium of the pulmonary arteries. Other 
reports of FcRn expression in the mouse lung are also contradictory, 
with some reporting expression over the entire lung and others 
reporting no pulmonary expression (Kuo & Avensen, 2011). There is 
however very strong evidence for the presence of FcRn on alveolar 
macrophages (Spiekermann, et aI., 2002). 
It is therefore not certain whether the active transcytosis pathway for 
IgG is present in the mouse lung. However, work by (Bitonti & Dumont, 
2006) has shown decreased transport of inhaled Fc conjugated 
molecules out of the lung when the IgG-FcRn interaction is disrupted 
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by mutation of histidine 435 to alanine. This suggests that the active 
transport pathway is present, however the capacity of the pathway is 
not currently known. 
1.5.5 Importance of the location of the site of action 
One further area of complication in determining the ideal distribution of 
, 
an inhaled antibody is that different biologics will require different final 
distribution within the lung, which is ultimately dependent on the 
location of the target. For example, an antibody inhaled for lung cancer 
treatment would need to be preferentially taken up into the tumour. 
(Maillet, et aI., 2011) have shown that inhaled cetuximab is able to 
penetrate tumours in the lung in vivo and has strong anti-tumour 
activity. Another example is inhaled granulocyte-macrophage colony-
stimulating factor (GM-CSF) a potential treatment for patients with 
cystic fibrosis, which is expected to act in the alveoli. GM-CSF cannot 
be dosed via the IV route, due to its high water solubility and large size 
severely limiting the percentage of the dosed drug able to cross from 
the bloodstream into the alveoli (L Heslet & Nepper-Christensen, 
2012). Inhalation is a convenient way to deposit the desired dose 
directly into the alveoli, avoiding this problem. 
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1.6 Conclusions from the literature regarding pulmonary 
clearance of proteins 
The factors determining the distribution of inhaled biologics within the 
respiratory system are not currently clearly defined and understood 
(Patton, et aI., 2010). At present, very few biologics are formulated for 
inhalational delivery and their distribution within the lung has tended to 
, 
be determined on a case by case basis rather than by investigation of 
the underlying mechanisms. Often formulations are optimised for 
inhalational delivery based upon desired PKlPD parameters, with no 
investigation into distribution mechanisms being undertaken. 
The surface area of the respiratory tract is very large and antibodies 
ought to be able to cross the mucosal lining and enter systemic 
circulation, avoiding first pass degradation in the liver. However, 
inhalation would also be an ideal delivery route for antibodies against 
pulmonary targets, where delivery would be directly to the local site of 
action. This could reduce the dose of antibody required and therefore 
the cost of the treatment as, with systemic administration of antibody, 
only a small fraction of the total dose would reach the lining of the 
respiratory tract. In turn this ought to reduce the levels of systemic 
toxicity and side effects seen with some current antibody therapeutics. 
27 
1.7 Investigating inhalation as a potential delivery route for 
antibodies 
In general it can be considered that there are two different conditions 
under which antibodies could be delivered by inhalation: 
1 :- In a situation where it is desirable for the antibody to be retained 
in the lung at high concentrations, for example, when the antibodies 
are directed against pulmonary targets, for instance in asthma or 
chronic obstructive pulmonary disease (COPD) treatment. 
2 - In a situation where it is desirable for the antibody to be rapidly 
absorbed into systemic circulation, as was the case for inhaled insulin. 
In order to determine whether inhalation is a feasible delivery route, in 
either of the conditions discussed above, it is necessary to obtain 
information about the fate of an antibody following inhalation. 
SpeCifically, knowledge is required regarding the rates of antibody 
transport out of the lung, and the mechanisms by which this transport 
occurs. Once this information is available then it should become 
possible to determine the major factors influencing pulmonary antibody 
clearance and provide strategies to manipulate pulmonary retention 
time. 
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1.8 Animal models of lung disease 
In the situation where therapeutic antibodies are delivered by inhalation 
to treat pulmonary disease, the lung encountered by the antibody is 
expected to differ from the normal healthy lung. As such one of the 
aims of this work is to investigate the pulmonary transport of antibodies 
in, the diseased lung. This can be achieved in vivo using mouse models 
of lung disease. The most commonly used models of the diseased lung 
are those models designed to mimic the airway inflammatory and 
remodelling changes observed in human asthma (Zosky & Sly, 2007). 
Asthma is an allergic, chronic inflammatory airway disease with several 
characteristics including, airway inflammation which is eosinophilic in 
nature, airway hyperresponsiveness (excessive constriction of the 
airway smooth muscle in response to spasmogens), acute sudden 
onset airway obstruction that can be fatal if not reversed and 
underlying structural changes within the lung (Fish & Peters, 1999) 
(Fanta, 2009). These structural changes are termed airway remodeling 
and involve fibrosis in the airway walls, goblet cell hyperplasia, smooth 
muscle thickening and increased collagen deposition (Bousquet, et aI., 
2000). Asthma is generally considered to be Th2 driven, with the 
immune response being driven by IL-4, IL-5, IL-9 and IL-13 and leading 
to both increased serum IgE levels and to the production of allergen 
specific IgE (Barnes, 2001). 
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There are numerous animal models of asthma available across a 
variety of species, including the mouse (Bates, et aI., 2009), rat (Martin 
& Tamaoka, 2006), guinea pig (Ricciardolo, et aI., 2008), dog 
(Chapman, 2008) and monkey (Coffman & Hessel, 2005); However, no 
current animal model reflects all the hallmarks of human asthma. 
1.8.1 Mouse models of asthma 
, 
The mouse is a convenient species for the study of asthma, as there 
are a wide variety of mouse specific reagents available, which aids in 
the analysis of ex-vivo samples and there is also detailed knowledge 
available of both mouse physiology and genetics (Busse & Holgate, 
2008). Mice do not spontaneously develop asthma, however numerous 
studies have shown that mice can be sensitised to a wide range of 
antigens, including ovalbumin (Kumar, et aI., 2008), LPS (Smith & 
Herschman, 2004), house dust mite extract (Johnson, et aI., 2004) and 
ragweed (Yadav, et aI., 2009). Protocols generally involve sensitisation 
of animals to allergen, followed by allergen challenge and can be split 
into either acute or chronic models. 
1.8.2 Acute mouse models 
Acute mouse models of asthma generally last over 7-14 days. 
Sensitisation is usually achieved in the presence of an adjuvant, which 
reduces both the time and dose required for sensitisation (Blyth, et aI., 
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1996). Additionally, adjuvants such as aluminium hydroxide have been 
shown to drive the formation of a Th2 based immune response, which 
is characteristic of human asthma (Fuchs & Braun, 2008). The 
allergen (usually ovalbumin) and adjuvant are usually given via the 
intraperitoneal route as systemic sensitisation has been shown to be 
more rapid and robust than for example inhalational sensitisation. 
Following sensitisation the animal is challenged by inhalation of the 
., 
allergen. 
Acute mouse models do result in some of the changes observed in 
human asthma, including airway inflammation, goblet cell hyperplasia, 
airway hyper-responsiveness (AHR) and high levels of IgE. However, 
the airway remodeling observed in asthmatic patients is not present 
and both airway inflammation and hyper-responsiveness can resolve 
following the final challenge (McMillan & Lloyd, 2004). Acute models 
have been used to successfully probe the underlying cell signaling 
mechanisms involved in asthma, identifying numerous targets for 
research into novel asthma treatments. However, several treatments 
which function in the acute mouse model have proven ineffective in 
clinical trials. For example acute mouse models highlighted IL-5 as a 
key factor in the development of AHR, with IL-5 knock out mice not 
developing AHR or allergic airway inflammation (Foster, et aI., 1996) 
(Cho, et aI., 2004), however IL-5 antagonists had less clinical benefit 
than expected, with no effect observed on the forced expiratory volume 
in patients (Kips, et aI., 2003). 
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1.8.3 Chronic mouse models 
Chronic exposure protocols were developed as an attempt to 
overcome the limitations of the acute mouse models. The chronic 
exposure protocols aimed to reproduce the airway remodeling 
observed in human disease in the hope that this would result in models 
that were more predictive of efficacy in the clinic (Lloyd, 2007). 
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Ovalbumin (Wegmann, 2008) and HOM (Kim, et aI., 2009) are the most 
commonly used allergens in the chronic mouse models, with ovalbumin 
given intraperintoneally, subcutaneously or intranasally with aluminium 
hydroxide three times per week over an average of 2 - 3 months (Nials 
& Uddin, 2008). 
In these chronic ovalbumin models, protocols have been carefully fine 
tuned to minimise tolerance to the allergen developing, which generally 
involves careful control of the dose of allergen received, especially via 
the intranasal route (Kumar, et aI., 2008). HOM extract is generally 
given intranasally, 3 - 5 times per week over 5 - 10 weeks (Rydell-
Tormanen, et aI., 2008). There has been no evidence of tolerance to 
HOM developing, perhaps due to HOM being an allergen to which 
animals would ordinarily be exposed. This also makes HOM extract a 
more clinically relevant allergen and it is important in the development 
of human asthma (Saglani, et aI., 2009). However, the fact that HOM is 
a clinically relevant allergen is of less importance than developing a 
clinically predictive mouse model of asthma. 
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Both the ovalbumin and HOM chronic models result in the development 
of some of the features of human asthma. There is a predominantly 
Th2-dependent allergic response, with marked eosinophilia in the 
airways and robust AHR (Nials & Uddin, 2008). Importantly there is 
significant evidence of airway remodeling with goblet cell hyperplasia, 
smooth muscle hypertrophy and epithelial metaplasia (McMillan & 
L ~ o y d , , 2004). In contrast to the acute models, the inflammatory and 
airway remodeling changes observed in the chronic models have been 
shown to persist following delivery of the final dose of allergen (Kumar, 
et aI., 2004). As yet no novel compounds tested in the chronic mouse 
models have been tested in the clinic, however the response to 
corticosteroids (McMillan & Lloyd, 2004), leukotrieine antagonists 
(Henderson, et aI., 2002) and phosphodiesterase 4 inhibitors (Herbert, 
et aI., 2008) is in line with what is observed in the clinic. 
1.8.4 Strain differences 
One complication in the development and implication of mouse models 
of asthma is variation in response to allergen between strains (Boyce & 
Austen, 2005). Ultimately the optimal protocol for sensitisation and 
challenge must be determined independently for each strain 
(Shinagawa & Kojima, 2003). BALB/c mice have been shown to 
develop increased levels of AHR than C57BLl6 mice in response to the 
same ovalbumin sensitization and challenge protocol (Takeda, et aI., 
2001). In contrast, levels of eosinophils and neutrophils recoverable in 
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bronchoalveolar lavage fluid (BAlF) are greater in C57BU6 mice than 
BAlB/c (Gueders, et aI., 2009). Additionally, there are differences 
observed in the cytokine expression levels between the two strains with 
BAlB/c showing increased Il-4, Il-5, Il-13, and CCl11 expression 
levels and C57BU6 showing higher CCl11 and CCl5 expression 
(Gueders, et aI., 2009). 
1.9 Imaging pulmonary antibody clearance in vivo 
There are a number of imaging techniques currently available, which 
can provide a great deal of information about the structure and function 
of organs and systems within the body. In this project, the focus is on 
delivery to the lung, therefore information regarding lung structure, 
function and both the pulmonary and systemic distribution of inhaled 
antibodies over time is desirable. This can be achieved by making use 
of both Computed Tomography (CT) and Single Photon Emission 
Computed Tomography (SPECT) imaging to provide structural 
information regarding the lung and information regarding the spread of 
inhaled antibodies after instillation. 
1.9.1 SPECT/CT 
A CT scan is in essence a 3D X-ray, determining the X-ray density of 
each specific point and creating a 3D representation of these density 
differences. Areas of high density, such as bones, show up bright white 
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and areas of low density, such as the air filled lungs, show up black. 
CT scans provide very high levels of detail regarding the anatomy of a 
test subject, either human or animal (Delbeke & Isreal, 2009). 
A SPECT scan produces a result similar to a CT scan, in that SPECT 
measures the density of radiation at specific points and builds up a 3D 
r ~ p r e s e n t a t i o n n of the distribution of radiation within a subject. In most 
cases a gamma emitting isotope, such as 99mTc or 1231 is introduced 
into a subject and its progress followed over time using SPECT 
(Chatziioannou, 2005). SPECT is used extensively in the pre-clinical 
testing of pharmaceuticals (Franc, et aI., 2008) and in clinical settings 
to image myocardial perfusion, tumours and brain activity (Mariani, et 
al.,2010). 
By combining the anatomical detail of a CT scan with the radioactivity 
map from a SPECT image, the radioactivity within a subject can be 
localised. The two images (CT and SPECT) must be generated with 
the subject in a fixed position, so that the images can be fused. The CT 
image 'is in essence a 3D X-ray of the animal and provides anatomical 
information, which is overlaid with the 3D radioactivity map provided by 
the SPECT image. This results in an easily interpretable qualitative 
picture of the 3D distribution of the radiolabel within the animal, the 
results of which can be quantified in terms of levels of radioactivity 
within a given region of interest. 
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In this project a combination of CT/SPECT will be used to provide both 
structural data regarding the anatomy of the animal from CT and 
functional data of pulmonary antibody clearance from SPECT, using 
radiolabelled antibodies. By overlaying the CT and SPECT images the 
distribution of the radiolabelled antibody can be determined within the 
animal over time. 
A radiolabel will need to be introduced to the antibodies investigated in 
order to facilitate SPECT imaging. The chemistry to introduce the 
radioactive isotope 99mTc onto various proteins, including antibodies is 
well established (Mather & Ellison, 1990). The reaction is a two step 
process where disulphide bridges in the antibody hinge region are 
reduced to give free thiol (-SH) groups, which are then reacted with 
technetium to give the radiolabelled antibody. 
1.9.2 SPEeT imaging 
SPECT imaging is based on the detection of gamma radiation which is 
emitted from the nucleus of radioactive isotopes during radioactive 
decay. Gamma rays are detected by scintigraphy and the detector in 
the SPECT imager is a single thallium doped sodium iodide crystal 
(DePuey, et aI., 2000). When a gamma ray hits the crystal the energy 
is sufficient to excite an electron from the valence band to the 
conductance band. When the excited electron returns to the ground 
state a photon is released. This causes the generation of a flash of light 
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when a gamma ray hits the crystal and is termed scintigraphy (Knoll, 
2010). Detection of the emitted photons results in current generation 
and the magnitude of the current generated at each point over the 
surface of the detector produces a map of intensity proportional to the 
intensity of gamma ray emission in the subject being imaged. 
qne drawback of using scintillation as a detection method is that any 
incident gamma ray hitting the detector results in current generation, in 
reality it in necessary to constrain the incident radiation in order to 
produce a clear image. In order to accurately relate the current 
generated to a specific location within the subject it is necessary to limit 
the gamma rays hitting the detector to those which are emitted 
perpendicular to the detector. This is achieved using a collimator. In 
SPECT imaging, a collimator generally consists of a sheet of lead 
drilled with small (3-5 mm) holes, which covers the entire detector. 
Lead effectively blocks gamma rays, so only radiation parallel to the 
holes (perpendicular to the detector) reaches the crystal (Knoll, 2010). 
In small animal imaging, where the subject is small compared to the 
size of the detector, a pinhole collimator is generally employed. This 
limits the detectable gamma rays as described above, but also acts to 
magnify the detected image in a similar way to how a pinhole camera 
projects an optical image. A schematic of a pinhole collimator can be 
seen in Figure 1.9. 
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Figure 1.9 - Diagram showing effect of pinhole collimator in SPECT imaging. 
In order to build up a 3D image the detector is rotated around the 
subject. Usually two detectors are held parallel on opposite sides of the 
subject and rotated around 180°, this results in a 360 0 image generated 
in half the time taken for one detector to travel 360°. 
1.9.3 CT Imaging in small animal models of asthma 
CT imaging presents a non-invasive method to assess the extent of the 
structural and functional changes that occur in rodent models of lung 
disease. The inflammatory changes in the lung observed in small 
animal models of asthma have the effect of increasing airway 
thickness, which has been shown to result in changes in lung density in 
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CT images (Jobse, et aI., 2009). Lung density can therefore be used as 
a useful biomarker of disease progression in these models (Riesenfeld, 
et aI., 2010). 
Collecting a CT image of an animal is not a terminal procedure, unlike 
histology or functional assessment of pulmonary resistance and 
c,Ompliance using forced manoeuvres, which allows for repeat 
assessments in the same animal over time. CT imaging therefore 
presents a potential method to reduce the number of animals required 
in studies to characterise the effect of allergens in the mouse lung. 
39 
1.10 Aims and Objectives 
The overall aim of this project is to determine whether inhalation is a 
feasible route of delivery for therapeutic antibodies, particularly 
antibodies against pulmonary targets. 
ty10re specifically, the aim is to produce a reliable experimental and 
data analysis procedure to accurately determine the redistribution 
pattern of an inhaled antibody in vivo, which can be applied to any 
antibody and in models of diseased lungs. 
This principal aim can be further broken down into the following 
objectives: 
• To establish a set of techniques which, when combined, can be 
used to analyse the pulmonary clearance of any antibody 
• To establish a method for radio-labeling antibodies, which is 
, simple, fast and stable in vivo over at least 24 hours. 
• To collect baseline transport data for an inhaled, whole, 
monoclonal antibody, in the healthy lung 
• To investigate the mechanisms by which antibodies cross the 
lung epithelium by: 
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o Investigating passive diffusion by comparing the 
pulmonary retention of antibody fragments and small 
proteins of differing molecular weights and 
o Exploring the role of transcytosis of antibodies by FcRn 
by comparison of transport data for studies using mutant 
antibodies with different binding affinities to FcRn. 
• To determine the effect of disease on antibody retention in the 
lung, determining if lung residency is expected to be sufficiently 
long to allow successful treatment of asthma/COPD. 
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1.11 Thesis structure 
Chapter 1 - General introduction, review of the relevant literature and 
statement of aims and objectives 
Chapter 2 - Expression and purification of the proteins required for 
tne SPECT/CT imaging experiments - including mutant IgG, antibody 
fragments and the FN3 protein 
Chapter 3 - Set-up and validation of the chemistry to introduce a 
radiolabel into the antibody, followed by preliminary imaging 
experiments to assess the stability of the radiolabelled antibody over 
24 hrs. 
Chapter 4 - SPECT/CT imaging results for the pulmonary clearance 
rate of a whole monoclonal IgG. Investigation of the mechanism of 
pulmonary antibody clearance using antibody fragments and mutant 
IgG with different binding affinities to mFcRn. 
Chapter 5 - Further characterisation of the murine HDM model of 
asthma with CT imaging and assessment of antibody clearance from 
the diseased lung. 
Chapter 6 - Summary of the data generated, overall conclusions and 
suggestions for future work. 
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CHAPTER 2: Production of reagents for use in 
the in vivo imaging experiments 
2. Overview 
This chapter details the work undertaken to produce the reagents 
r:equired for the in vivo imaging experiments designed to determine 
antibody retention in the lung following intratracheal instillation. 
A whole mouse IgG1 was provided by Medlmmune, UK. In addition to 
this two sets of reagents were produced: 
For the studies designed to determine the importance of passive 
diffusion as a pulmonary clearance method two antibody fragments 
were produced. These were the Fab and scFv fragments of the IgG1 
provided by Medlmmune as well as the FN3 protein, a single 11 kDa 
domain of the protein fibronectin with a structure similar to an Ig like ~ ~
sandwich fold. 
For the studies to determine the importance of the mFcRn receptor in 
pulmonary antibody clearance three mutant versions of the mouse 
IgG1 were expressed. The three mutants produced were: (1) an 
improved mFcRn binder (2) a decreased mFcRn binder and (3) a null 
binder. 
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2.1 Introduction 
As described in the general introduction in Chapter 1, there are two 
main pathways by which an inhaled antibody would be expected to 
cross the pulmonary epithelium. The first pathway is via passive 
diffusion, the second is transport through the epithelial cells via 
r,eceptor mediated transcytosis by FcRn. One of the major aims of this 
work was to determine the relative contributions of these pathways to 
antibody transport out of the lung. 
2.1.1 Investigation of passive diffusion as a transport 
mechanism for the pulmonary clearance of antibodies 
The pulmonary epithelium is not heterogeneous; for example, the 
epithelium lining in the trachea is ciliated pseudostratified columnar 
epithelium and is approximately 60 IJm thick. In contrast the main cell 
type lining the alveoli, the type I cell is roughly 0.2 IJm deep (Ehrhardt, 
et aI., 2008). Practically it is not possible to investigate passive 
diffusion across discrete areas of the pulmonary epithelium in vivo and 
as a result the imaging studies will only determine an average 
contribution for passive diffusion to antibody transport out of the lung. 
This will be an average value covering transport across the tracheal, 
conducting airway and alveolar epithelia. 
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Passive diffusion in general is faster for smaller molecules and slower 
for larger molecules, with the rate of passive diffusion inversely 
proportional to the molecular weight. The basis for this dependence on 
molecular weight, as determined by Fick's Law, is described in more 
detail in section 1.5.1. 
In order to determine whether passive diffusion is an important 
mechanism in the pulmonary clearance of antibodies, the transport of 
the whole antibody will be compared to the transport of antibody 
fragments. The Fab (50 kDa) and scFv (28 kDa) fragments of the 
whole IgG (150 kDa) model antibody were expressed, the structures of 
which are shown in Figure 2.1. 
The FN3 protein, an 11 kDa single domain of fibronectin will also be 
tested, in order to provide clearance data for a species smaller than an 
scFv. The FN3 protein is a single domain of fibronectin type III, which 
contains the same Ig-like beta sandwich fold, as the antibody 
fragments, although the number and arrangement of the outer strands 
differs from those found in the antibody variable domains (Clarke, et 
aI., 1999). 
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• 
IgG (150 kDa) Fab (50 kDa) scFv (28 kDa) FN3 (11 kDa) 
Figure 2.1 - Pictures showing the structures and relative sizes of the proteins 
which will be investigated in the SPECT/CT imaging studies. Blue colour 
signifies antibody constant regions, green colour signifies antibody variable 
regions and red colour signifies Fibronectin III regions. 
If the whole IgG is transported out of the lung by diffusion controlled 
processes then comparison of the results for these two fragments and 
the whole IgG are expected to show linear trends. One complication is 
that there are two possible passively diffusion controlled pathways that 
an antibody could be transported out of the lung by (Patton, 1996). 
Firstly there is diffusion between the epithelial cells and secondly there 
is non-specific transcytosis through the epithelial cells. Although it will 
not be possible to differentiate between these two pathways, the extent 
to which passive transport is important in pulmonary antibody 
clearance, is obtainable. 
2.1.2 Investigation of transcytosis by mFcRn as a mechanism 
for the pulmonary clearance of antibodies 
In contrast to passive diffusion controlled transport, receptor mediated 
transcytosis is an active uptake mechanism where a receptor 
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specifically transports a molecule through a cell. The mFcRn receptor 
is known to actively transcytose mlgG across multiple cell types, 
including the pulmonary epithelium (Roopenian & Akilesh, 2007). 
In order to determine whether transcytosis by mFcRn is an important 
pathway in the pulmonary clearance of antibodies, mutant versions of 
the original whole IgG are required. Several single amino acid point 
mutations to the heavy chain of mlgG1 antibodies have been shown to 
alter binding to mFcRn and based upon mutations detailed in the 
literature three useful mutations were identified (Oall'Acqua, et aI., 
2002). The V250Q mutant where valine 250 is mutated to glutamine is 
known to improve binding of mlgG1 to mFcRn. The H435A mutant 
where histidine 435 is mutated to alanine shows either completely 
ablated or significantly reduced binding to mFcRn. The double mutant 
H435A_1235A where both the histidine 435 and isoleucine 253 
residues have been mutated to alanine has been shown to completely 
ablate binding to mFcRn. 
As these mutants would have differing binding affinities to mFcRn if 
transcytosis by mFcRn is important in pulmonary antibody clearance, 
then transport out of the lung ought to be faster for improved mFcRn 
binders (V250Q) and slower for reduced or null mFcRn binding 
mutants (H435A and H435A_1253A), when compared to wild type 
(WT). As a minimum, if active transcytosis by mFcRn is involved in 
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pulmonary antibody clearance, then the clearance profiles of these 
mutant mlgG would be expected to differ. 
2.2 Materials and methods 
2.2.1 Materials 
The following were provided by Medlmmune, UK 
• Whole IgG heavy chain in the expression vector pEU 23.3. 
• Whole IgG light chain in the expression vector pEU 22.2. 
• Purified Fab-HIS10 heavy chain DNA in nuclease free water. 
• Purified scFv-HIS10 DNA in nuclease free water. 
• FN3cys2-HIS10 protein in pET expression vector. 
• Forward and reverse oligonucleotides of the correct sequence to 
introduce the desired point mutations (H435A, 1253A and 
V250Q) into the whole mlgG1 heavy chain. 
• M20A feed - proprietary CHO cell medium containing FBS and 
glucose, designed to provide optimal protein expression in CHO 
cells. 
• Biotinylated mouse FcRn complexed with mouse beta-2-
microglobulin (the stable in vivo form of the receptor). 
For expression the following media were used: 
• 2TY media (per litre): 
10 g yeast extract, ·16 g tryptone, 5 g NaCI in distilled water. 
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• Super broth (per liter): 
24 g yeast extract, 12 g bacto-tryptone, 5 mL glycerol, 72 mM 
potassium phosphate dibasic, 17 mM potassium phosphate 
monobasic, 100 mL 20% glucose. 
2.2.2 Methods 
2.2.2.1 Preparation of DNA for transfection and/or 8DM 
Whole IgG heavy chain in the expression vector pEU 23.3 and whole 
IgG light chain in the pEU 22.2 expression vector were provided by 
Medlmmune UK. 1 IJL of each was transformed into z competent DH5a 
E.coli cells as follows: 
2TY agar plates were dried at 37°C and a single aliquot of DH5a z-
competent cells were thawed on ice. A total of 100 IJL DH5a cells per 
transformation were transferred to pre-chilled microfuge tubes on ice 
and 2 IJL DNA was added to each aliquot of cells. The cells were mixed 
gently before incubation on ice for 10 min. Then 50 IJL cells from each 
transformation were plated and grown overnight at 37°C. A single 
colony was picked from each 2TY agar plate and grown for 8 hours in 5 
mL 2TY medium plus 100 IJg/mL ampicillin. 
The DNA was harvested used a Qiagen mini-prep kit according to the 
following protocol (Qiagen, 2006). The cells were pelleted for 10 min at 
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2000 g in a bench top centrifuge and the supernatant discarded. The 
pellet was re-suspended in 0.5 mL 2TY medium and transferred to a 
1.5 mL microfuge tube. The cells were re-pelleted at 3500 g for 5 min 
in a table-top microfuge and the media removed. The cells were re-
suspended in 250 IJL buffer P1 and 250 IJL buffer P2 and the tube 
inverted 4 times to mix thoroughly. 350 IJL buffer N3 was added, the 
tube inverted 4 times until a homogenous colourless suspension was 
achieved, then the tube was centrifuged at 3500 g for 10 min in a table 
top microfuge. The supernatant was transferred to a Qiagen mini-prep 
column, centrifuged for 1 min and the flow through discarded. The 
column was washed with 0.5 mL buffer PS, centrifuged for 1 min and 
the flow through discarded. The column was washed with 0.75 mL 
buffer PE, centrifuged for 1 min and the flow through discarded. The 
column was centrifuged for a further 1 min, to remove any residual 
wash buffer and the flow through discarded. The column was 
transferred to a fresh microfuge tube and 50 IJL nuclease free water 
added to the centre of the column, allowed to stand for one min, then 
centrifuged for 1 min. 
DNA concentrations were then measured by absorbance at 260 nm. 
The absorbance of a 50 IJg/ml double stranded DNA solution at 260 nm 
is 1.0 and this relationship can be used to determine the concentration 
of the unknown DNA sample. 
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2.2.2.2 Site directed mutagenesis 
Site directed mutagenesis (SDM) was used to introduce point 
mutations to the IgG WT heavy chain DNA. The SDM was achieved 
using a polymerase chain reaction (PCR) method. In general, a PCR 
mix was set up with 1 jJL heavy chain DNA template at 50 jJg/ml, 2.5 
jJL DMSO (5%), 25 jJL, 2x Phusion mastermix (New England BioLabs 
Inc.), 17.5 jJL NFW and 2 jJL each of the appropriate forward and 
reverse oligonucleotides at 100 ng/ml. A negative control of PCR mix 
using 4 jJL NFW instead of oligonucleotides was also used. Optimum 
conditions used in the PCR reactions varied for each mutation. 
For the PCR to generate the H435A mutant, the conditions were as 
follows: initial denaturation at 98°C for 30 s, followed by 30 cycles of 
denaturation at 98°C for 10 s, annealing at 60°C for 20 sand 
elongation at 72°C for 5 min, final elongation was then at 72 °c for 10 
min. 
For the V250Q mutant, the conditions used in the PCR reaction to 
correctly produce the mutant were: initial denaturation at 98°C for 30 s, 
followed by 30 cycles of denaturation at 98°C for 10 s, annealing at 55 
°c for 20 s and elongation at 72°C for 5 min, final elongation was then 
at 72 °c for 10 min. 
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To give the double mutant, the 1253A mutation was introduced into the 
H435A mutated heavy chain DNA. The PCR mix was prepared as 
before, using the H453A heavy chain DNA as the template and the 
PCR reaction run using the same conditions as for the original 
introduction of the H435A mutation into the WT heavy chain DNA. 
.,Following the PCR reaction 1 IJL Dpnl was added to each reaction to 
facilitate digestion of the template plasmid and digestion allowed to 
proceed at 37°C for 1 hour. Then 5 IJL of each reaction was 
transformed into z competent DH5a cells, plated onto 2TY agar plates 
and grown overnight at 37°C (as described in detail in section 2.1.1) 
Provided that -no colonies had grown on the negative control plate, 
single colonies from the reaction plates were picked and grown 
overnight in 5 mL 2TY media, plus 100 IJg/mL ampicillin. Mini-preps of 
the DNA from each clone were completed as described in section 2.1.1 
and sequenced. Sequencing results were analysed in Sequencher 4.0. 
2.2.2.3 CHO cell expression of proteins 
All of the mutant antibodies and antibody fragments produced were 
expressed in a Chinese hamster ovary (CHO) cell line. For all protein 
expressions 500 mL CHO cells in CD-CHO medium (Invitrogen), at a 
density of 1 x1 06 cells/mL were prepared in roller bottle culture vessels 
with 0.05 mM penicillin and 0.05 mM streptomycin antibiotics. 
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For the scFv fragment, purified DNA was diluted to a concentration of 
62.5 IJg/mL in 8.2 mL CD-CHO medium (Sigma Aldrich). 8.2 mL of the 
transfection promoter poly(ethylenimine) (PEl) (Sigma Aldrich) at 720 
IJg/ml) was added to the diluted DNA, vortexed for 10 s and added to 
the 500 mL of CHO cells after a one minute incubation at room 
temperature. 
For expression of the mutant IgG heavy chain DNA encoding the 
desired mutation, was diluted to 30 IJg/mL in 8.2mL CD-CHO medium. 
Wild type light chain DNA was also prepared at 30lJg/mL in 8.2mL CD-
CHO medium. 8.2 mL PEl at 360 IJg/mL was added to both the heavy 
and light chain DNA. The DNA/PEl mixes were vortexed for 10 s before 
being added directly to the same 500 ml CHO cells following a one 
minute incubation period at room temperature. 
For the Fab fragment, the above procedure for whole IgG mutants was 
repeated using Fab heavy chain DNA, as provided by Medlmmune UK. 
Both the cultures for the fragments and mutants were then fed with 
M20A medium (as described in section 1.1) according to the following 
schedule: 100 mL per 500 mL culture 4 hrs post transfection, 50 mL 
per 500 mL culture 3 days post transfection and 100 mL per 500 mL 
culture 7 days post transfection. After 10 days, the cell culture 
supernatants were harvested by centrifugation at 2000 g for 30 min. 
The supernatants were then clarified by filtration through a 0.2 IJm filter 
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to sterilise and to remove any cell debris. Finally supernatants were 
then concentrated to approx 1200 mL using a 10,000 Oa diafiltration 
unit, then diluted to 4000 mL with OPBS and concentrated back to 200 
mL. 
2.2.2.4 Bacterial expression of the FN3 protein 
1 ~ L L of the FN3cys2 protein in pET vector provided by Medlmmune UK 
was added to 5 0 ~ L L BL21 (OE3)star E.coli, incubated for 30 min at room 
temperature then heat shocked at 42°C for 45 seconds. 0.45 mL 2TY 
media was added and the transformation incubated at 37°C for 1 hour 
with shaking at 300 rpm, before 2 ~ L L of the transformation was plated 
onto 2TY+100 ~ g / m l l ampicillin agar plates and incubated overnight at 
37°C. 
A scraping of cells from the transformation plate was added to 100 mL 
2TY+100 ~ g / m L L ampicillin media to form a starter culture and grown 
overnight at 37°C with shaking at 250 rpm. The final expression was 
completed in 4 x 400 mL flasks containing superbroth medium (as 
described in section 3.1) with 100 ~ g / m L L ampicillin. 10 mL of the starter 
culture was added, then grown at 37°C with shaking at 250 rpm for 2 
hours. The optical density was read and if between 0.6 and 1, then 
IPTG was added to a final concentration of 0.2 mM. Cells were 
incubated at 28°C for a further 4 hours with shaking at 250 rpm before 
centrifugation at 2000 g for 10 minutes. The supernatant was discarded 
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and 30 mL BugBuster (Novagen) plus 20 IJL Iysonase and 10 IJL 
benzonase was added to each of the 4 cell pellets. The cells were re-
suspended in the lysis mixture and centrifuged at 10,000 g for 30 
minutes to pellet insoluble debris. Finally, the lysed cell solution was 
clarified by filtration through a 0.2 IJm filter. 
,2.2.3 Purification 
2.2.3.1 Protein A affinity chromatography 
A 5ml MabSelectSure (GE Healthcare) column was equilibrated with 
25 mL cold DPBS (Sigma-Aldrich). The column was then connected to 
an AKTA explorer FPLC chromatography system (GE healthcare). The 
concentrated cell culture supernatant was loaded onto the column at a 
flow rate of 4 mUmin. The loaded column was then washed with 25 mL 
DPBS at 4 mUmin in order to remove any unbound proteins. The 
column was then washed with 5 column volumes of PBS, followed by 5 
column volumes of 50 mM sodium acetate buffer at pH 5.4. This higher 
pH wash removes bound impurities from the column, leaving behind 
bound antibody which was then eluted with 5 column volumes of 50 
mM sodium acetate buffer at pH 3.65. 2 ml elution fractions were 
collected and neutralised with addition of 100 IJL 0.05 M Tris buffered 
saline at pH 9.0, to increase the pH of the eluted fractions to 
approximately pH 7.0. This increase in pH improves antibody stability 
and decreases the risk of protein precipitation. 
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2.2.3.2 Nickel affinity Chromatography 
Two Hi-trap columns (GE Healthcare) were connected in series. The 
concentrated cell culture supernatant was loaded onto the columns at a 
flow rate of 4 mUmin. The columns were washed with 5 column 
volumes 2xDPBS and connected to an AKT A explorer FPLC 
,chromatography system (GE healthcare) The following buffers were 
prepared: Buffer A = 2xDPBS and Buffer B = 2xDPBS + 400 mM 
imidazole. Columns were washed with 2 column volumes 0% buffer B, 
followed by 10 column volumes 10% Buffer B. A gradient elution was 
performed over 10 column volumes from 10-100% buffer B. Finally the 
columns were washed with 2 column volumes 100% buffer B. 
2.2.3.3 Size exclusion chromatography 
A Superdex 75 16/60 gel filtration column (GE Healthcare), was loaded 
onto an AKTA explorer FPLC chromatography system (GE healthcare) 
washed with 1.5 column volume milliQ water and equilibrated with 1.5 
colurrln volumes DPBS. The protein-containing fractions from the 
protein A purification were pooled and concentrated to 7 mL in 
centrifugal concentrators with a 50 kDa molecular weight cut off and 
mixed with 1 mL 1 M TCEP solution. The concentrated, TCEP 
incubated solution was then loaded onto the gel filtration column in a 
10 mL loop and an isocratic elution over 1 column volume was 
performed in DPBS, at 2.5 mllmin, collecting 3mL elution fractions. 
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2.2.4 SOS-PAGE 
Fractions eluted from the columns during the protein purifications were 
screened by SOS-PAGE to determine whether they contained the 
protein of interest. 15 IJL of each protein containing fraction, plus 
samples of the concentrated media initially loaded onto the column and 
,of the column flow-through, were mixed with 5 IJL 4xLOS loading buffer 
(Invitrogen) and boiled for 2 minutes. Samples were run on a 4-12% 
bis-tris NuPAGE gel (Invitrogen), in 1x NuPAGE MES SOS running 
buffer (Invitrogen) for 40 min at 200 V and 400 rnA with the SeeBlue 
ladder (Invitrogen) as a reference. The gel was stained with instant 
blue (Invitrogen) and destained in MiIIiQ water. 
2.2.5 Endotoxin removal using a polymixin B - agarose column 
10 mL Polymixin B agarose resin (Sigma Aldrich) was manually packed 
into a disposable plastic column (Sigma Aldrich) and the column 
washed with 100 mL OPBS. 2.5 mL concentrated FN3 protein in OPBS 
was loaded onto the column, before elution with 5ml cold OPBS. 
2.2.6 Endotoxin testing 
The endotoxin levels within the final protein samples were tested using 
an Endosafe Endotoxin Quantifier and Endosafe Endotoxin Test 
Cartridges (both Charles River). The quantification of the levels of 
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endotoxin present in the samples is based upon the reaction of 
endotoxin with Limulus Amoebocyte Lysate (LAL), the reaction is 
colourimetric with the colour intensity proportional to the amount of 
endotoxin present in the sample and calibrated to a standard curve. 
The test reports the total Eu/mL sample and performs a spike control 
test which compares an aliquot of test sample to a known endotoxin 
,standard. This test is included to ensure that the test sample does not 
react unexpectedly with the LAL substrate giving artificially high or low 
endotoxin level readings. This is important as several common 
additives, such as EDT A, can affect the accuracy of the test (Charles-
River, 2003). 
The protein sample was diluted 1:2 in endotoxin free water and 50 IJL 
loaded into each of the four lanes in the endotoxin testing cartridge. 
The results displayed are the endotoxin level in the sample in Eu/mL 
and sample %CV. In addition, for the control test, the results are 
displayed as Spike Eu/Ll, Spike %CV and Spike Recovery%. 
To be suitable for in vivo use the endotoxin test for the sample must 
report: %CV less than 25%, spike %CV less than 25%, % spike 
recovery between 50-200% and a final Eu/mg less than 50. 
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2.2.7 Octet experiments to determine binding affinities of whole 
IgG mutants to mFcRn 
Whole IgG mutants were prepared at 400, 200, 100, 50, 25, 12.5 
ng/mL in OPBS + 0.002% Tween 20 at either pH 6.0 or pH 7.4. 
Biotinylated mFcRn was prepared at 10 J.jg/mL again in OPBS + 
,0.002% Tween 20 at either pH 6.0 or pH 7.4. Two different protocols 
were run: association at pH 6 with dissociation at pH 6 and association 
at pH 7.4 with dissociation at pH 7.4. 
The assay is fully automated, and involves: hydrating the streptavidin 
biosensors in assay buffer (OPBS at the desired pH) followed by 
loading of the biotinylated mFcRn onto the streptavidin sensors and 
gathering of a corresponding baseline for the coated sensors by 
immersion in fresh assay buffer. The coated sensors are then 
immersed in sample solution and the association of the two proteins 
measured, finally the coated sensors are immersed into fresh assay 
buffer and the dissociation of the two proteins measured. 
Measurements are based on biolayer interferometry (see section 4.4 
for details). 
Results for protein association and dissociation for each sensor are 
background corrected and the mean total of IgG bound to the sensors 
is plotted for each mutant, expressed as a percentage of the binding of 
WT IgG to mFcRn. 
59 
2.3 Results and Discussion 
The Fab and scFv fragments as well as the whole IgG mutants were 
expressed in CHO cell culture and purified by column chromatography 
from the concentrated cell culture supernatants. Antibody fragments 
were purified by nickel affinity chromatography. Whole IgG were 
,purified with Protein A affinity chromatography. Size exclusion 
chromatography was used as a secondary purification step if the 
protein product from the initial purification was not sufficiently pure. 
The basic principle behind the column purifications is the same in both 
the protein A and nickel affinity columns, however the chemical make-
up of the columns differs to take into account the nature of the protein 
to be purified. In brief the columns contain a matrix designed to bind to 
the target protein in a specified buffer but to disassociate in a different 
buffer. This allows for selective binding of the target protein, followed 
by controlled elution of the protein from the column (Kastner, 2000). 
Protein A affinity columns were used to purify the whole IgG mutants. 
The columns are packed with beads coated in protein A, which binds to 
the Fc region of whole IgG at pHS.4 but disassociates at pH3.6S. The 
antibody containing solution is loaded onto the column at pHS.4, and 
binds to the protein A coated beads. The column is washed with buffer 
at pHS.4 to remove any unbound proteins from inside the column and 
the purified antibody is then eluted from the column at pH 3.65. 
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The Fab and scFv fragments were expressed with a 10-HIS tag in 
order to allow purification by nickel affinity chromatography. In a nickel 
affinity or HIS-trap column, gel beads are coated with NiS04. In the 
presence of water this results in free Ni2+ ions on the surface of the 
beads. The nickel ions strongly bind histidine in aqueous conditions, 
however in the presence of imidazole the binding is disrupted and the 
"bound protein desorbs from the column (GE-Healthcare, 2005). 
Size exclusion chromatography was used as a secondary purification 
step if the initial purification did not result in sufficiently pure protein. In 
a size exclusion or gel filtration column, the column is packed with 
small gel beads, which do not bind to the target protein. Instead 
separation is based on molecular weight. Smaller molecules are more 
easily caught in the pores between the gel beads, with larger 
molecules diffusing more easily through the column (Kastner, 2000). 
2.3.1 Protein expression 
2.3. { 1 Expression and purification of the Fab fragment 
The Fab fragment (50 kDa) was expressed with a 10-His tag in CHO 
cells and purified by nickel affinity chromatography as described in the 
methods section. The elution trace from the nickel affinity column is 
shown in Figure 2.2 and shows removal of impurities in fractions A 1-
A12 before elution of the Fab fragment from fractions C1 to C12, 
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together with the SDS-PAGE gel showing the protein concentrations of 
the fractions of interest as well as initial load and column flowthrough. 
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Figure 2.2 - Nickel affinity column elution trace for the Fab fragment (50 kOa), 
_ showing the elution of product from Fractions C1-C12 as well as the 
corresponding SOS-PAGE gel of the protein containing fractions, concentrated 
cell culture supernatant, diafilter flow through and column flow though. 
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It can be seen in the gel, in figure 2.2, that the eluted fractions are 
significantly cleaner than the initial load and column flow through. The 
strong bands at 50 kOa show the presence of the Fab fragment, 
however the protein is not particularly pure, as evidenced by the 
presence of numerous other sized bands on the gel. It was therefore 
decided to further purify the protein with gel filtration. Fractions C3-C10 
,were pooled, concentrated and incubated with TCEP, before 
undergoing gel filtration, the results of which can be seen in Figure 2.3. 
TCEP is a mild reducing agent which inhibits disulphide bridge 
formation, stabilising free thiols (-SH). The Fab fragment, as well as the 
scFv fragment and FN3 protein contain free cysteine (-SH containing) 
residues. The- cysteines on nearby molecules in solution can interact, 
via disulphide bridge formation, leading to dimerisation of the product. 
Addition of TCEP to the pooled fractions aimed to promote monomer 
formation, minimising protein aggregation and increasing yield. 
As seen in Figure 2.3, the Fab fragment eluted from the SEC column in 
fractions 01-12. The corresponding gel for these fractions shows the 
presence of a 50 kOa band, indicating the presence of the Fab 
fragment. The lower MW bands show protein which has reduced in the 
gel. It was assumed that this is due to boiling the samples before 
loading onto the gel. Fractions 04-011 were pooled and concentrated 
to 7 ml in a 10 kda cut off centrifugal concentrator. The final yield was 
determined by A280 to be 75mg. 
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Figure 2.3 - Size exclusion purification elution trace for the Fab fragment (50 
kOa). showing elution of product from Fractions 01-012 as well as the 
corresponding 50S-PAGE gel of the protein containing fractions and the 
original Nickel affinity purified protein load. 
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A quality control gel was run to determine the purity of the expressed 
protein, and is shown in Figure 2.4. The gel shows that the protein is 
of the expected molecular weight and the reduced lanes show two 
bands of the correct Mw to correspond to the heavy and light chains. 
From the gel the protein purity was assessed as 99% due to the lack of 
contamination bands in either the 5 j.Jg or 1 j.Jg lanes. 
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14 
1 2 3 4 5 6 
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2 - 5ug Fab 
3 -1ug Fab 
4 -ladder 
5 - 5 ug Fab reduced 
6 - 1 ug Fab reduced 
Figure 2.4 - QC gel for Fab fragment (50 kDa). Both non reduced lanes show 
bands at the correct Mw of 50 kDa, reduced lanes show two bands of approx 25 
kDa (one for Fab heavy chain and one for Fab light chain) 
The endotoxin levels were determined, as detailed in section 2.2.6 to 
be 1.028 Eu/mg. The maximum permitted endotoxin level in a product 
designed to be used in vivo is 50 Eu/mg therefore this very low level of 
endotoxin means that the Fab fragment is safe to use in the in vivo 
_ images studies. 
In conclusion the purity, endotoxin levels and yield of the Fab fragment 
are all sufficient for the imaging studies. 
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2.3.1.2 Expression of the scFv fragment 
The protein was expressed with a 10-His tag in CHO cells and purified 
by nickel affinity chromatography and SEC, as described in the 
methods section. Figure 2.S shows the elution trace from the His trap 
column, showing impurity removal in fractions A8-12 and scFv elution 
,in fractions C7-DS. 
The elution peak shows a shoulder, which indicates the presence of an 
impurity. The corresponding gel shows that the eluted protein is not 
pure, but there is a strong band at the correct molecular weight (28 
kDa). It was therefore decided to proceed with further gel filtration 
purification. Fractions C11-D4 were pooled, concentrated, incubated 
with TCEP, before loading onto a gel filtration column, the results of 
which are shown in Figure 2.6. 
The elution trace in Figure 2.6 shows two peaks, a large elution peak, 
with a second shoulder. Fractions covering both peaks were run on the 
gel shown in figure 2.6. The gel shows the presence of the scFv in 
fractions C6-DS, these were concentrated to Sml in a 10kda cut off 
centrifugal concentrator. The final yield was determined by A280 to be 
42mg. 
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Figure 2.5 - Nickel affinity purification elution trace for the scFv fragment (28 
kOa), showing elution of product from Fractions C7 -05 as well as the 
corresponding 50S-PAGE gel of the protein containing fractions, concentrated 
cell culture ~ u p e r n a t a n t , , diafilter flowthrough and column flow through. 
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Figu're 2.6 - Size exclusion purification elution trace for the scFv fragment (28 
kOa), showing the elution of product from fractions C6-0S as well as the 
corresponding 50S-PAGE gel of the protein containing fractions, column flow 
through and the original nickel affinity purified protein loaded. 
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A quality control gel was run to determine the purity of the expressed 
protein, and is shown in Figure 2.7. The gel shows that the protein is 
of the expected molecular weight at 28 kDa, the non-reduced lane 
shows a high molecular weight impurity at 60kDa, however as this is 
not present in the reduced lanes and is of double the scFv Mw it can 
be assumed that this is dimer formation. From the gel, the protein 
, purity was assessed as 99% due to the lack of contamination bands in 
either the 5 IJg or 1 IJg lanes. 
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Figure 2.7 - QC gel for the scJ='v fragment (28 kDa). All lanes show a band at the 
correct Mw of 28 kDa. The non-recued lanes show an additional band at approx 
55 kDa, suggested to be dimer formation. 
The endotoxin levels were assessed as described in section 2.2.6, and 
determined to be 0.731 Eu/mg. The maximum permitted endotoxin 
level in a product designed to be used in vivo is 50 Eu/mg therefore 
this very low level of endotoxin means that the scFv fragment is safe to 
use in the in vivo images studies. 
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In conclusion the purity, endotoxin levels and yield of the scFv 
fragment are all sufficient for the imaging studies. 
2.3.1.3 Expression and purification of FN3 protein 
The FN3 protein was expressed with a 10-His tag in BL21(OE3)star 
, E.coli and purified by nickel affinity and size exclusion chromatography 
as detailed in the materials and methods sections. The elution trace 
from the nickel affinity column is shown in figure 2.8 with the 
corresponding 50S-PAGE gel for the protein containing fractions. 
The elution trace shows protein eluted form the column in fragments 
C7 -04, w h e r ~ ~ there is one main elution peak with a significant 
shoulder. The gel confirms the presence of an 11 kOa band 
corresponding to the correct molecular weight for the FN3 protein in 
addition to bands at 2 and 3 times the correct molecular weight. It was 
assumed that these represented dimer and trimer formation. As the 
protein was not sufficiently pure a further gel filtration purification, 
preceded by incubation with TCEP to remove dimer and trimer 
formation, was run. The elution trace and gel for this run are shown in 
figure 2.9. 
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Figure 2.8 - Nickel affinity purification elution trace for the FN3 protein (11 kOa), 
showing elution of product from Fractions C6-04 as well as the corresponding 
50S-PAGE gel of the protein containing fractions, concentrated cell culture 
supernatan! and column and diafilter flowthroughs. 
71 
188 
98 
62 
49 
38 
28 
17 
14 
6 
49 
8 
8 
7 
4 
Elution of product 
Elution of impurities 
1 2 3 4 5 6 7 8 9 10 11 12 
2 3 4 5 6 7 8 9. 10 11 12 
1 -ladder 
2 - E1 
3- 012 
4 -011 
5- 010 
6- 09 
7 - 08 
8- 07 
9- 06 
10- 05 
11 - 04 
12 -ladder 
1 -ladder 
2- E2 
3 - E3 
4 -E4 
5- E5 
6- E6 
7 - E7 
8 - E8 
9- E9 
10 - E10 
11 - E11 
12 -ladder 
Figure 2.9 - Size exclusion purification elution trace for the FN3 protein (11 
kOa), showing the elution of the product from fractions 012-E9 as well as the 
corresponding 50S-PAGE· gel of the protein containing fractions. 
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The results of the gel filtration purification shown in figure 2.9 
demonstrate that there is a large amount of protein at the correct 
molecular weight that appears very clean. There is a small amount of 
dimer formation present, but far less than in the nickel affinity 
purification gel. The final yield of protein as assessed by A280 
measurement was 53 mg. 
A QC gel was run to test the purity of the final FN3 protein and is 
shown in Figure 2.10. The gel shows protein of the expected molecular 
weight at 11 kDa, and the protein purity was assessed as 99 %. 
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Figure 2.10 - QC gel for the FN3 protein (11 kDa), showing a single band at 11 
kDa in all lanes. 
Endotoxin levels were expected to be high in the expressed FN3 
protein, as expression was carried out in E.coli. Therefore the purified 
protein was passed through a polymixin-b agarose column to remove 
endotoxin. Following this the endotoxin levels in the sample were 
assessed as described in section 2.2.6, and determined to be 0.20 
Eu/mg. The maximum permitted endotoxin level in a product designed 
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to be used in vivo is 50 Eu/mg therefore this very low level of endotoxin 
means that the FN3 protein is safe to use in the in vivo images studies. 
In conclusion the purity, endotoxin levels and yield of the FN3 protein 
are all sufficient for the imaging studies. 
,2.3.2 Production and testing of mutant IgG with differing 
binding affinities to the mFcRn receptor. 
Site directed mutagenesis was used to induce point mutations into the 
heavy chain DNA of the whole IgG to alter binding to the mFcRn 
receptor. The mutations attempted had been previously shown to alter 
mFcRn binding. The PCR based site directed mutagenesis described 
in the methods section resulted in clones with the following mutations, 
IgG_H435A, IgG_V250Q and IgG_H435A_1253A, which were then 
expressed in CHO cell culture and purified by Protein A 
chromatography, as described in the methods section. 
2.3.2.1 Expression and purification of the H435A mutant 
The supernatant from the CHO cell cultures was concentrated and 
loaded onto Protein A affinity columns as described in the methods 
section. The elution trace and corresponding gel for the protein A 
affinity purification can be seen in Figure 2.11, which shows a large 
amount of antibody present in the elutions from fractions A4-A7, which 
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is very clean. However, there is also some antibody remaining in the 
flow through from the protein A column, which indicates incomplete 
loading of the antibody onto the column. 
4 
3 
2 
AI 
... 
123 4 567 
Elution of final product 
.. 
16,0 
AID All 
" . 
8 9 10 11 12 
6 '--___ _ _ - - - - - - - ~ ~
j 
e • 
" . 
1 - ladder 
2 - Diafilter filtrate 
3 - concentrated supernatant 
4 - flow through 
5 - A3 
6 - A4 
7-A5 
8 - A6 
9 - A7 
10-A8 
11 - A9 
12 - A10 
Figure 2.11 - Protein A purification elution trace for the H435A mutant (150 
kOa), showing elution of product from Fractions A3-A 10 as well as the 
corresponding 50S-PAGE gel of the protein containing fractions, concentrated 
cell culture supernatant and diafilter and column flow through. 
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The antibody containing fractions from this initial protein A purification 
were pooled and stored at 4 °C whilst the column flow through was re-
loaded onto the protein A column and a second protein A purification 
completed. The elution trace and corresponding gel are shown in figure 
2.12. 
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Figure 2.12 - Repeat protein A affinity purification elution trace for the H435A 
mutant (150 kOa), showing elution of product from Fractions A2-A10 as well as 
the corresponding 50S-PAGE gel of the protein containing fractions, the flow 
through from the 1st pass and column flow through. 
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As seen in Figure 2.12 there is less antibody present in the 2nd pass, 
however some additional antibody has been recovered from the flow 
through, improving the total yield of antibody. It should be noted that 
the interaction between protein A and IgG involves the Fc region of the 
IgG. It is possible that the H435A mutation introduced into the antibody 
is reducing the binding affinity with protein A and making purification 
\ more challenging. 
All H435A mutant antibody containing fractions were pooled and the 
yield determined by A280 to be 19.84 mg. 
A quality control gel was run to determine the purity of the expressed 
protein, and is shown in Figure 2.13. The gel shows that the protein is 
of the expected molecular weight at 155 kDa. The reduced lanes show 
the expected bands for the He at 50 kDa and light chain at 20 kDa. 
From the gel, the protein purity was assessed as 95 % due to the 
presence of contamination bands in the 5 I-Ig but not the 11-1g lanes. 
The endotoxin levels were assessed as described in section 2.2.6, and 
determined to be 0.330 Eu/mg. The maximum permitted endotoxin 
level in a product designed to be used in vivo is 50 Eu/mg therefore 
this very low level of endotoxin means that the H435A mutant antibody 
produced is safe to use in the in vivo images studies. 
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Figure 2.13 - QC gel for the IgG_H435A mutant (150 kDa). Non reduced lanes 
show a band at the correct Mw of 150 kDa. Reduced lanes show two bands, one 
at approx 50 kDa corresponding to the heavy chains and one at approx 20 kDa 
corresponding to the light chains. 
The purity, endotoxin levels and yield of the IgG_H435A mutant are all 
sufficient for the imaging studies. 
2.3.2.2 Expression and purification of the IgG V250Q mutant 
The supernatant from the CHO cell cultures was concentrated and 
loaded onto protein A affinity columns as for the H435A mutant and as 
described in the methods section. The elution trace and corresponding 
gel for the purification can be seen in Figure 2.14. 
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Figure 2.14- Protein A purification elution trace for the V250Q mutant (150 
kOa), showing elution of product from Fractions A 1-A 11 as well as the 
corresponding SOS-PAGE gel of the protein containing fractions, and column 
load and flow through. 
The gel in Figure 2.14 shows a very large amount of antibody present 
in the elution from the column, which is reasonably pure. The largest 
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antibody containing fractions (A3,- 8) and the final yield determined by 
A280 as 28.02 mg. 
A QC gel was run and is shown in Figure 2.15. From this the protein 
was assessed as >95 % pure, due to the faint contamination bands in 
the 5 I-Ig but not the 11-1g lanes. The endotoxin levels were determined, 
, as described in section 2.2.6, to be 0.54 Eu/mg. 
In conclusion the purity, yield and endotoxin levels are sufficient for use 
in the imaging experiments. 
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Figure 2.15 - QC gel for the IgG_V250Q mutant (150 kOa). Reduced lanes 
show two bands, one at approx 50 kOa corresponding to the heavy chains and 
one at approx 20 kOa corresponding to the light chains. 
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2.3.2.3 Expression and purification of the H435A 1253A double 
mutant 
The supernatant from the CHO cell culture was concentrated and 
loaded onto a protein A column as described previously. The elution 
trace and corresponding gel can be seen in Figure 2.16. 
Elution of final product 
"....J J _1 -..l 
1 2 3 4 5 6 7 8 9 10 11 12 
188 
98 
62 
49 
38 
28 
17 
14 
6 
-
1 - ladder 
2 - load 
3 - flow through 
4-1 
5 - 2 
6 - 3 
7-4 
8 - 5 
9 - 6 
10 - 7 
11 - 8 
12 - 9 
Figure 2.16 - Protein A purification elution trace for the H435A_1243A mutant 
(150 kOa), showing elution of product from Fractions 1-9 as well as the 
corresponding 50S-PAGE gel of the protein containing fractions, and column 
load and flow though 
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The gel shows that there is antibody present in the elutions, which is 
very clean, however there is also antibody remaining in the 
flowthrough, indicating incomplete loading onto the column. This is the 
same result as seen with the H435A mutant and could be attributed to 
the mutations disrupting the IgG-protein A interaction. 
A 2nd pass of the flowthrough, through the protein A column was 
completed, with the following elution trace and again with manual 
fraction collection. The results are shown in Figure 2.17. 
Figure 2.17 shows that there was additional antibody purified from the 
second pass, however this was at very low levels. All antibody 
containing fractions were pooled and the final yield was determined by 
A280 to be 1.53 mg. This is a very low yield, however there is sufficient 
protein to dose six animals at two time points in the in vivo imaging 
studies. In the interest of time the expression was not repeated. 
A quality control gel was run to determine the purity of the expressed 
protein, and is shown in Figure 2.18. The gel shows that the protein is 
of the expected molecular weight at 150 kOa. The reduced lanes show 
the expected bands for the He at 50 kOa and light chain at 20 kOa. 
From the gel the protein purity was assessed as 95 % due to the lack 
presence of contamination bands in either 1 J,Jg lanes. 
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Figure 2.17 - Repeat protein A purification elution trace for the H435A_1253A 
mutant (150 kOa), showing elution of product from Fractions 1-A8 as well as the 
corresponding 50S-PAGE gel of the protein containing fractions, the flow 
through from the 1st pass and column flow through 
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Figure 2.18 - QC gel for the H435A_1253A mutant (150 kDa). Reduced lanes 
show two bands, one at approx 50 kDa corresponding to the heavy chains and 
one at approx 20 kDa corresponding to the light chains. 
The endotoxin levels were assessed as described in section 2.2.6, and 
determined to be 0.899 Eu/mg, this very low level of endotoxin means 
that the double mutant antibody produced is safe to use in the in vivo 
images studies. 
In conclusion the purity, endotoxin levels and yield of the 
IgG_H435A_1253A fragment are all sufficient for the imaging studies. 
2 . ~ . 3 3 Assessment of the levels of mFcRn binding of the whole 
IgG mutants 
The octet red system from Biorad was used to determine kinetics of 
binding between biotinylated mFcRn and the whole IgG mutants. The 
system measures the kinetics of association and dissociation between 
two proteins, where one biotinylated protein is immobilised on 
streptavadin coated biosensors. In this case, biotinylated mFcRn is 
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immobilised on the streptavidin sensors and the binding of the mutant 
IgG to the immobilised mFcRn monitored with biolayer interferometry. 
Biolayer interferometry works by comparing the profile of reflected light 
from the biotin-mFcRn coated sensor to a reference material. As the 
mutant IgG binds to the immobilised mFcRn, the optical density above 
the sensor changes, altering the pattern of the reflected light. Changes 
in the reflected pattern of light are proportional to the amount of IgG 
bound to mFcRn and association/dissociate plots can be generated of 
the interaction between the antibody and receptor. From these the 
relative binding and dissociation constants of the IgG-mFcRn 
interaction can be plotted for each mutant. 
Figure 2.19 shows an original association and subsequent dissociation 
plot for WT IgG over the full range of IgG concentrations. In the graph 
the wavelength of the reflected light (in nm) is plotted over time. Each 
green line represents the response of an individual sensor, with each 
concentration of IgG was tested in duplicate. 
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Figure 2.19 - Graph showing association/dissociation of WT IgG to Octet 
streptavidin sensors coated with mFcRn over the full range of IgG 
concentrations at pH 7.4. Each green line represents the response recorded for 
an individual sensor. The red line represents removal of the sensor from IgG 
containing solution and immersion in fresh buffer. 
Figure 2.19 clearly shows an initial phase of binding of WT IgG to 
FcRn, as evidenced by an increase in the response, which reaches a 
plateau. Additionally, the response is higher for sensors immersed in 
higher concentration IgG solutions, indicating that more IgG is binding 
to the immobilised mFcRn. 
After 500 seconds the sensor is removed from the IgG solution and 
transferred to buffer (shown with a red line on the graph in figure 2.19). 
At this point in the graph the IgG can be seen to dissociate from the 
immobilised mFcRn, as evidenced by a decrease in response. 
The aim of this experiment was to determine to what extent the H435A, 
V250Q and H435A_1253A mutants bind mouse FcRn compared to wild 
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type IgG. The amount of IgG bound to each sensor after 500 seconds 
was compared for each mutant at each concentration. The results were 
tabulated in Graphpad Prism 5 and expressed as % response of the 
WT IgG to give relative binding of the mutants ± sem. The results can 
be seen in Figure 2.20 and show that the V250Q mutation has 
improved binding affinity to mFcRn to 163.2 ± 17.4 % relative to the 
WT IgG. The H435A mutation has greatly reduced the binding affinity 
to mFcRn to 11.5 ± 5.2 % and the double mutation has completely 
ablated binding to the mFcRn receptor. 
WT V250Q H435A H435A_1253A 
Figure 2.20 - Pooled results from Octet analysis of binding affinity for WT IgG 
and mutants to mFcRn, at pH 6 and 7.4. Data shows the relative binding 
affinities to mFcRn as a percentage of the WT binding. Error bars represent ± 
sem (n=12 per bar) 
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It can be concluded from these results that a panel of IgG with differing 
binding affinities to mFcRn have been produced for use in the in vivo 
imaging experiments. 
2.4 Conclusion 
In summary, the work detailed in this chapter has resulted in the 
successful expression of the reagents required for the in vivo imaging 
experiments. The yield, purity and endotoxin levels of each of the 
proteins expressed are sufficient for in vivo use. Additionally, the panel 
of mutant antibodies for the transcytosis by mFcRn experiments exhibit 
a good range of binding affinities to mFcRn in vitro. 
The next chapter details the work up and validation of the chemistry 
required to radiolabel proteins for use in the in vivo imaging studies, as 
well as investigating the stability of the radiolabelled proteins in vivo. 
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CHAPTER 3: Set up and Validation of in vivo 
Imaging Experiments 
3. Overview 
This chapter details the work undertaken to set up and validate the 
imaging technique used to study antibody transport out of the lung in 
vivo. 
The overall aim of the work described in this chapter was to determine 
whether labelling an antibody with technetium reproducibly produced a 
construct which was stable over the period required in the imaging 
experiments. Additionally, control experiments to assess the effect of 
the presence of the technetium label on antibody transport/binding 
were completed. 
3.1 Introduction 
Before work could begin on imaging the redistribution of an intra-
tracheally instilled antibody in vivo it was necessary to thoroughly 
validate a suitable labelling method to introduce a radiolabel into the 
antibody of interest. The SPECT imaging technique used, as described 
in section 1.9.1, produces a map of the distribution of radioactivity 
within the animal. The antibody of interest does not possess any 
radioactive atoms and as such it is necessary to introduce a radiolabel 
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to allow detection of the antibody during imaging. Common radiolabels 
are gamma emitting isotopes of technetium (99mTc), iodine C231) or 
gallium (67Ga). The isotope 99mTc was chosen for this work as it was 
readily available and research by (Mather & Ellison, 1990) determined 
a simple and reproducible two step process to add technetium labels to 
antibodies. The original method proposed utilises f3-mercaptoethanol to 
reduce the disulphide bridges at the hinge region in the antibody, then 
the reduced antibody is reacted with technetium to give the final 
labelled antibody. f3-mercaptoethanol has an unpleasant odour and 
today is commonly replaced with the alternative reducing agent Tris(2-
carboxyethyl)phosphine (TCEP). As TCEP will be used to reduce the 
antibody in this work, it is necessary to carefully re-validate the 
chemistry used to generate the labelled antibody to ensure that this 
alteration to the original method is suitable. 
Once generated, the technetium labelled antibody is only suitable for 
use in the imaging experiments if the label remains associated with the 
antibody over the course of the experiment. As such it is necessary to 
determine the in vivo stability of the construct over time. Another 
important factor is that the technetium label must not greatly affect the 
conformation of the antibody, and alter either its binding to target 
antigen or its transport out of the lung. It was therefore necessary to 
validate the technetium labelled antibody to ensure its suitability for the 
imaging experiments. 
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3.2 Materials and Methods 
3.2.1 Materials 
Antibodies and antibody fragments were produced as detailed in 
Chapter 2. Technetium was supplied as sodium pertechnetate 
(NaTc04) in saline solution by the radiopharmacy departments at either 
the Queens Medical Centre, Nottingham or The Christie Hospital, 
Manchester. 
3.2.2 Methods 
3.2.2.1 Reduction of antibody and fragments 
5 mg antibody (or fragment) was reduced by reaction with 20 ~ L L 0.1 M 
TCEP, for 30 min at room temperature. The reduced antibody/fragment 
was purified by gel filtration through a PD-10 desalting column (GE 
Healthcare), eluting with 3.5 mL cold, deoxygenated DPBS and the 
success of the reduction determined by colorimetric assay with 
Ellman's reagent. 
3.2.2.2 Ellman's Assay 
The assay determined the concentration of free thiol groups on the 
reduced antibody. Ellman's reagent was prepared as a 1 mM solution 
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in 100 mM phosphate buffer at pH B.O. Samples were tested in 
duplicate, with 10 IJL sample diluted with 90 IJL Ellman's reagent. The 
standard for the colourimetric assay was 1 mM cystine hydrochloride in 
100 mM phosphate buffer at pH B.O and standards points were 
measured between 1000 IJM and 1 IJM. The SoftMax Pro 4.6 software 
package calculated the mean concentration of thiol groups for an 
unknown sample, based upon the slope of the standard curve. This 
was used to determine the number of reduced thiols per antibody using 
the following formula: 
Reduced thiols per molecule = (measured thiol conc. M x molecular 
weight) / protein concentration mg/mL 
The reduced antibody was then stored in 0.5 mg aliquots under 
nitrogen at -BO °C until required and defrosted just prior to reaction with 
technetium. 
3.2.2.3 Production of the final conjugate 
An MOP vial, (GE healthcare) containing sodium medronate and tin 
chloride, was reconstituted with 5 mL 0.9 % saline and 50 IJL 
MOP/saline was added to 0.5 mg reduced antibody/fragment. Sodium 
pertechnetate solution (approx. 400 MBq) was added to the 
antibody/MOP solution and allowed to react for 10 min at room 
temperature. During this reaction the sodium pertechnetate was 
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reacted with the strong reducing agent tin (II) chloride in the presence 
of medronic acid, to give a medronate-technetium chelate with 
technetium in the 4+ oxidation state. The technetium chelate was 
further reacted with the reduced antibody, with the technetium 
chelating with the free thiol groups in the antibody hinge region 
producing the final labelled antibody. 
The radiochemical purity of the tagged antibody, a measure of the 
success of the tagging reaction, showing what percentage of antibody 
has been successfully tagged, was assessed using Thin Layer 
Chromatography (TLC). 
3.2.2.4 Thin layer chromatography 
1 IJL of tagged antibody, diluted to give an activity of 30-100 kBq /IJL, 
was spotted onto TLC plates and the TLC run with a 0.9 % saline 
mobile phase until the solvent front reached the line at the top of the 
plate, after approximately 20 min. The TLC plate was cut in half and 
the activity of each half recorded with a well counter, radiochemical 
purity was then calculated as: 
Radiochemical Purity (RCP) % = 100 x [Activity at RtO / (Activity at Rf1 
+ Activity at RtO)] 
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The RCP should be greater than 90 % in all cases and any batch with 
an RCP of <80 % was discarded. 
TLC separates free and bound technetium based upon differences in 
solubility in saline solution. Free technetium is highly soluble in saline, 
whereas technetium bound antibody is highly insoluble. Free 
technetium has an Rf value of 1, whereas radiolabelled antibody has 
an Rf of O. There are no other labelled components in the reaction 
mixture and as such the plate contains technetium at either Rf 0 or 1 
with no substances having an Rf between 0 and 1. 
A small sample of the reaction solution was spotted onto a cellulose 
coated TLC plate, and the plate stood vertically in the saline mobile 
phase. Any 99mTc not associated with the antibody moves up the TLC 
plate with the solvent front, whereas any 99mTc remaining associated 
with the antibody remains in the spot at the bottom of the plate, as 
shown in Figure 3.1. 
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Figure 3.1 - Diagram showing principles of thin layer chromatography (TLC) 
3.2.2.5 Measurement of sample activity in the well counter 
A well counter was calibrated to 99mTc. Before testing the sample the 
background reading was recorded, then the samples placed directly 
inside the counter for approximately 10 seconds until a stable activity 
reading was recorded. The counter records the total activity of the 
sample in MBq. 
3.2.2.6 ELISA - to detect mlgG1 
Nunc maxisorb 96 well plates were coated with antigen diluted to 4 
~ g / m L L in DPBS overnight at 4-8 DC. Plates were washed 3 times with 
250 ul DPBS + 0.05% Tween 20 (DPBS-T), before blocking for 1 hour 
95 
with 2% marvel in OPBS (M-OPBS). Plates were washed with 3 x 
OPBS-T before addition of samples and standards. 
Standards were aliquots of antibody/fragment from the same batch as 
was dosed in the in vivo imaging study. Samples were mouse plasma 
and were tested in duplicate at dilutions of 4,8, 16 and 32-fold. 
Plates were washed 3 times with OPBS-T, before incubation for 1 hour 
at room temperature with anti mouse IgG1-HRP (binding site) diluted 
1 :6000 with M-OPBS. Plates were washed 5 x with OPBS-T, before 
addition of 50 IJL tetramethylbenzidine (liquid substrate for ELISA, 
Sigma-Aldrich UK), after 30 min at room temperature the reaction was 
stopped with addition of 50 IJL 1 M sulphuric acid and plates were read 
at 450 nm. 
Data was plotted in Microsoft Excel; the standard curve fit was a log/log 
plot with linear regression from 200 ng/ml to 0.2 ng/ml and the linear 
regression fit must have ~ ~ value of >0.95. Samples were calibrated 
from the standard curve and values multiplied by the dilution factor, 
sample CV should be s 15%. 
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3.2.2.7 Imaging on the planar gamma camera 
All in vivo experiments were performed in compliance with licences 
issued under the UK Animals (Scientific Procedures) Act 1986 
following local ethical review. 
Two female BALB/c mice (mean weight 19.9 ± 0.15 g) were terminally 
anaesthetised with 0.1 mLlkg ketamine/medetomidine mixture at a 
dose rate of 75 mg/kg ketamine and 1 mg/kg medetomidine. One 
animal was intratracheally instilled with 50 ~ L L labelled antibody at 0.5 
mg/mL in 0.9 % saline at approx 200 MBq/mL. The second animal was 
intratracheally instilled with 50 ~ L L sodium pertechnetate solution at 
approx 200 MBq/ml. The animals were placed supine on the planar 
gamma camera and imaged for 60 min, before being euthanised with 
an overdose of sodium pentobarbitone. 
Images were analysed in GammaVision+ (AMETEK, Inc.) with regions 
of interest (ROI) manually determined to cover the lungs, stomach, 
thyroid and bladder. The total activity within each ROI was determined 
over 1 minute segments of the total scan, with the first data point 
covering the time between 0 and 1 minute and the final data point 
covering the time between 59 and 60 minutes. Activities in each ROI 
were then plotted over the course of the experiment in an activity vs. 
time plot. 
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3.2.2.8 Comparison of pulmonary transport of labelled vs. 
unlabelled antibody after intratracheal instillation. 
All in vivo experiments were performed in compliance with licences 
issued under the UK Animals (Scientific Procedures) Act 1986 
following local ethical review. 
12 Female BALB/c mice (Charles River, UK, mean weight 21.7 ± 0.26 
g) were anaesthetised in an induction chamber with isoflurane. 
Anaesthetised animals were suspended by the front incisors on a titled 
board and intratracheally dosed by insertion of a dosing needle through 
the larynx with 50 IJL antibody at 0.5 mg/mL in PBS. 
Animals were allowed to recover from anaesthesia and returned to 
their home cages. Three animals were euthanized with an overdose of 
sodium pentobarbitone at each of 4 time points, 0, 1, 2 and 4 hours 
post dose. Blood was taken from the descending vena cava, spun 
down in a bench top centrifuge and the plasma stored at -80°C prior to 
analysis by ELISA. 
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3.3 Results and Discussion 
3.3.1 Validation of labelling chemistry with Ellman's reagent and 
TLC 
The chemistry to introduce a technetium label to the antibodies and 
fragments is a modified version of the protocol from (Mather & Ellison, 
1990). In brief the protein is reduced to release free thiol groups, which 
on reaction with technetium produce the radiolabelled antibody. The 
model antibody which was to be initially tested in the imaging 
experiments was labelled with 99mTc in a trial run of the conjugation 
chemistry, as described in the methods section. The reaction is a two 
step process, initially producing the reduced antibody and then further 
reacting this reduced species with technetium to yield the final labelled 
antibody. 
The first step of the chemistry is a reduction with TCEP, the success of 
which was determined using Ellman's assay. The assay is colourmetric 
with higher concentrations of free thiols producing a more intense 
yellow colour. Figure 3.2 shows the results obtained from Ellmans 
assay carried out on the reduced antibody, immediately following 
reaction with TCEP and after one month storage at -80°C, compared to 
the unreduced starting material. 
99 
Cone. thiol Standard Free thiol 
groups (..-M) deviation groups per 
molecule 
Unreduced IgG 7.5 3.316 0.62 ± 0.27 
Reduced IgG 65.1 9.395 5.39 ± 0.78 
Reduced IgG - after 58.9 8.126 4.87 ± 0.67 
1 month at -80· C 
Figure 3.2 - Data for IgG at 1.79 mg/mL, Mw of 148125. Table showing the 
values obtained from Ellman's assay of both reduced and unreduced antibody 
in triplicate, as well as a re-test of the same batch of reduced IgG after 1 month 
storage at -sooe. 
The number of free thiol groups per molecule of the unreduced 
antibody is 0.6, the reduced antibody contains 5.4 free thiol groups per 
molecule immediately after reduction and 4.87 free thiol groups after 
one month storage at -80°C. The increase in detectable free thiol 
groups after reduction indicates that the reaction has been successful. 
In addition, after storage under nitrogen at -80°C for 1 month no re-
oxidation of the free thiols occurred with a re-test of the number of free 
thiols present on the same batch of reduced IgG being the same within 
experimental error. 
The theoretical maximum number of free thiol groups available per 
molecule of reduced antibody is the number of thiols which can be 
produced from the reduction of the interchain disulphide bridges, plus 
the number of free cystine residues on the antibody. Each disulphide 
bridge reduction produces two free thiol groups. 
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The unreduced antibody shows 0.6 detectable thiols per molecule, 
therefore we can use 0.6 as the number of detectable cystine residues 
per molecule. The maximum number of thiols which can be released 
from the reduction of disulphide bridges is 8, 2 from each of the 4 
interchain disulphide bridges on a mouse IgG1. However, (Blauenstein, 
et aI., 1995) showed that reduction with TCEP under the conditions 
used here, results in selective reduction of the disulphide bridges at the 
hinge region. The disulphide bridges connecting the heavy and light 
chains are not reduced, minimising any potential conformational 
changes in the antigen binding domain and therefore any affect on 
antibody activity. This gives an expected number of free thiols for this 
antibody as 4 from the reduction of the 2 hinge region disulphide 
bridges, plus 0.6 free cystine residue. This is exactly in line with the 
observed results of 4-5 free thiols per molecule. 
The second stage of the labelling chemistry is the reaction of the 
reduced antibody with technetium in the presence of low affinity binding 
site blocking agents and a reducing agent. The percentage of 99mTc 
associated with the antibody was determined by comparison of the 
amount of activity at the bottom and top of the plate, as described in 
section 3.2.2.4. 
TLC was run on samples of the radiolabelled antibody after 0.5, 5 and 
24 hrs storage at room temperature in order to provide a preliminary 
assessment of the stability of the labelled antibody. Figure 3.3 shows 
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the results of the TLC experiments designed to determine the success 
of the final reaction to incorporate the technetium label into the reduced 
antibody, as analysed in the well counter. 
Activity at Activity at Radiochemical 
Rf1 (kBq/s) R,{} (kBq/s) Purity (%) 
After 0.5 hrs 0 12 100 
After 5 hrs 0 25 100 
After 24 hrs 0 28 100 
Figure 3.3 • Activities of bottom and top halves of TLC plates as determined by 
the well counter. Calculated RCP (%) are 100 % at all time points. 
As seen in Figure 3.3, analysis of the TLC plates using the well counter 
produced 100% calculated RCP for the labelled antibody tested at 0.5, 
5 and 24 hrs post reaction. This indicates that the labelled antibody is 
stable in solution for up to 24 hrs. Further validation experiments were 
then run to determine the stability of the labelled antibody in vivo. 
3.3.2 Experiments to validate the stability of the labelled 
antibody in vivo 
Several experiments were conducted to verify the in vivo stability of the 
labelled antibody. Initially the pulmonary clearance of intratracheally 
instilled labelled antibody was compared to that of intratracheally 
instilled free technetium with imaging on the planar gamma camera. 
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The planar gamma camera produces a 20 image of radioactivity within 
the animal. There is no resolution in the z direction and so the image is 
not.able to separate, for example, activity recorded in the lungs from 
activity in the tissue directly above and below the lungs. 
Figure 3.4 shows the distribution of free technetium within the same 
mouse over 46 minutes in graphical form, together with images taken 
at 1, 23 and 46 minutes post dose. The images provide the anatomical 
perspective required to determine the location of the activity signals 
within the animal. Regions of interest are drawn around areas 
representing specific organs and the changing level of activity recorded 
in these organs over the course of the scan, is represented in the 
accompanying graph. It is important to note that over the course of the 
experiment, the 99mTc is decaying. In order to account for this the 
figures were decay corrected, meaning that each figure was corrected 
back to show how much technetium would have been present in the 
sample at t=O. 
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Figure 3.4 - A series of gamma camera images showing a) the redistribution of 
free 99mTc within one m o u ~ e e over 46 minutes, with b) a graph quantifying the 
activity observed in different organs over 46 minutes. Activity is initally highest 
in the lung, dropping rapidly to a plateau at approx background levels after 30 
mins. Activity in the thyroid and stomach is initally very low increasing over the 
course of the scan. Activity in the bladder remains roughly constant at low 
levels throughout the scan. 
It can be seen in Figure 3.4 that in the image representing the first 
minute post dose, high levels of activity are present within in the lungs. 
This is expected from the intratracheal dosing method used, which 
delivers 100 % of the dose into the lungs. There is a low level of activity 
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throughout the animal, which is not localised in any specific region, as 
evidenced by the faint blue outline of the animal visible in the image. 
Thi.s represents technetium which has cleared the lung in the blood 
pool. The second image, representing the 22nd minute of the scan, then 
shows a further uptake of free technetium into the blood pool, which 
can be seen as the outline of the animal becoming increasingly clear 
as higher levels of the radioisotope reach the peripheral blood vessels. 
In addition, there is active uptake of technetium into the stomach and 
thyroid, which is a known occurrence and occurs via sodium iodide 
symporters (Franken, et aI., 2010). Finally, there is very poor lung 
retention observed, with the levels of activity in the lung decreasing 
markedly from the first image. The final image, representing the 45th 
minute of the scan, shows further uptake of the technetium into the 
stomach and thyroid, with levels of activity in the lung decreasing to 
become no higher than other highly perfused areas of the animal. This 
indicates that there is total pulmonary clearance of free technetium 
from the lungs between 23 and 46 minutes post dose. 
The graph in Figure 3.4 quantifies the trends observed in the images. 
Activity in the lungs drops by 70 % over 40 minutes, whereas activity in 
the stomach and thyroid increases by 420 and 300 % respectively. 
Activity in the bladder remains roughly constant over the course of the 
scan. The activity in the lungs reaches a plateau at 30 minutes post 
dose, which represents total clearance of the instilled technetium. The 
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observed decrease of 70 % underestimates the total level of clearance 
as the lungs are highly perfused and the 20 nature of the image 
rec.ords the total activity of the blood present in the entire upper thorax 
of the animal. Taking into account this overestimation of total activity in 
a given organ when there are high levels of activity present in the blood 
pool, the data still provides a re-distribution profile of free technetium in 
vivo over 46 minutes. 
The experiment described for free technetium was repeated for the 
technetium labelled antibody in order to compare the redistribution 
profile of the two species after intratracheal instillation. The graph in 
Figure 3.5 shows the total activity in specific organs over the course of 
the scan. 
The level of activity recorded in the lungs is high over the course of the 
scan, dropping by only 9 % over 46 minutes, as compared to a 70 % 
drop in activity recorded for the free technetium. Additionally, activity 
levels in the stomach and thyroid/larynx do not increase over the 
course of the experiment, in contrast to the increases observed for free 
technetium. As observed previously for free technetium no increase in 
activity is recorded in the bladder over the course of the scan. 
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Figure 3.5 - Graph showing the quantification of levels of activity within the 
lung, bladder, stomach and thyroid over the course of a 46 min scan. High 
levels of initial activity persist within the lung over the course of the scan. Very 
low levels of activity are recorded in the thyroid, stomach and bladder, which 
do not increase over 46 minutes. 
The redistribution pattern of the labelled antibody is therefore very 
different to that of free technetium, with far longer pulmonary retention 
and no build up of activity within the stomach or thyroid. This is 
important as a method to determine whether the technetium remains 
bound to the antibody in vivo and can be applied in two ways. Firstly as 
free technetium is cleared from the lungs within 30 minutes, if images 
of the distribution of labelled antibodies shows radiation remaining in 
the lungs for longer than 30 minutes it can be concluded that labelled 
antibody is stable, as it would be impossible to generate such images if 
the 99mTc tag had dissociated from the antibody. Secondly if the label 
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and antibody do dissociate later in the course of the experiment then a 
build up of activity in the thyroid is a suitable marker for this, as this is 
representative of the presence of free technetium. It is not possible to 
use build up of activity in the stomach as a marker of labelled antibody 
dissociation as one of the potential clearance methods for the instilled 
antibody is mucociliary clearance up the trachea and swallowing. 
However, conversely a build up of activity within the stomach, without 
accompanying build up of activity in the thyroid would be indicative of 
significant mucociliary clearance of the antibody. 
Overall these data provide initial evidence that the labelled antibody is 
stable in vivo, however the experiments only cover the first 46 minutes 
post dose. Further experiments were then run to determine labelled 
antibody stability in vivo out to 24 hrs post dose. 
3.3.3 Comparison of detection of construct in same plasma 
samples by ELISA or radioactivity measurements. 
The labelled antibody consists of two independently detectable parts, 
the antibody itself is detectable by ELISA and the label is detectable by 
measurement of total radioactivity within the sample. If the labelled 
antibody is stable over 24 hrs then determination of the concentration 
of labelled antibody in the same samples by both ELISA and total 
activity measurement should be equal. 
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An experiment was run to test this, with the concentration of labelled 
antibody determined in the same plasma samples, taken at 0, 2, 4 and 
24. hours post intratracheal instillation. The detection methods used 
were immediate quantification of the activity in the sample using the 
well counter to report an activity in 8q/ml or by ELISA to give antibody 
concentration in ng/ml. 
Figure 3.6 shows the results of these experiments normalised to the 
signal reported at time O. This normalisation is necessary to be able to 
compare the results of the separate detection methods on the same 
graph. The results show relative increases from baseline (t = 0) at 1,2, 
4 and 24 hrs post dose for each detection method. It is clear from the 
graph that within experimental error, concentrations determined by 
either detection method are equal. This is also demonstrated by the 
fact that comparison of the results for ELISA and radioactivity 
measurements using Student's unpaired t-test did not reach statistical 
significance (p>0.05) at any time point. 
The results of this experiment strongly indicate that the labelled 
antibody is stable in vivo over 24 hrs. However the presence of the 
label could still affect both the conformation and so binding ability of the 
antibody and/or transport of the antibody out of the lung. 
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Figure 3.6 - Comparison of detection of 99mTc_lgG by ELISA (detecting 
antibody) or by total activity of the sample as determined in the well counter 
(detecting the label). Expressed as % relative increase from t-=O with error bars 
of ± sem (n=6). The graph indicates that the level of radiolabelled antibody 
reported by either detection method is highly similar. 
3.3.4 Detection of known concentrations of IgG and 99mTc 
labelled IgG by ELISA to determine whether presence of 
label affects conformation 
If the presence of the technetium label affects the conformation of the 
antibody it could result in the data generated in the SPEeT imaging 
experiments not being representative of true pulmonary antibody 
clearance. 
An ELISA experiment was run comparing detection of known 
concentrations of whole IgG and labelled whole IgG. For the antibody 
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to be detectable in the ELISA, it must successfully bind to its target 
antigen and the Fc region of the antibody must successfully bind the 
anti-mouse Fc detection antibody. If the presence of the technetium 
label greatly alters the conformation of the antibody then it would be 
expected that these binding interactions would be disturbed and the 
concentration of labelled antibody determined by ELISA would be lower 
than for unlabelled antibody. 
The results of the experiment are shown in Figure 3.7 and show that 
within experimental error, the ELISA protocol returns accurate 
concentrations for both the labelled and unlabelled IgG between 50 
and 800 ng/ml. Comparison of the results for labelled and unlabelled 
antibody using Student's unpaired t-test did not reach statistical 
Significance (p>0.05) at any timepoint. This result indicates that the 
presence of the technetium label does not greatly affect the 
conformation of the antibody. 
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Figure 3.7 - Results of experiment comparing analysis of known 
concentrations of labelled and unlabelled antibody determined by ELISA. 
Graph shows that the ELISA reports correct concentrations of both labelled 
and unlabelled antibody, within experimental error. Error bars are ± sem (n=6). 
3.3.5 Experiments to confirm whether the presence of the 
technetium label affects antibody transport out of the lung 
l,n order for imaging to be a suitable method to determine the re-
distribution of an intratracheally instilled antibody, the presence of the 
tracer cannot interfere with antibody transport. A study was 
undertaken to confirm whether the presence of the technetium label 
would affect transport out of the lung. This compared levels of labelled 
and unlabelled antibody detected in the plasma of animals taken 0, 1, 2 
and 4 hours post dose. The data is shown in Figure 3.8 and shows an 
increase in plasma concentrations of both labelled and unlabelled 
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antibody over time. For the unlabelled antibody, the increase is from an 
average of 44 ng/mL at t=O to an average of 236 ng/mL 4 hours post 
dose, an overall 5.4-fold increase over 4 hours. This correlates well 
with the plasma levels of labelled antibody, which showed a 5.2-fold 
increase over 4 hours from 61 to 321 ng/mL. Comparison of the results 
for labelled and unlabelled antibody using Student's unpaired t-test did 
not reach statistical significance (p>0.05) at any timepoint. 
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Figure 3.8 - Graph showing that the concentration of labelled and unlabelled 
antibody detected by ELISA in plasma samples taken up to 4 hours post dose 
are highly similar. Error bars are ± sem (n=6). 
The results described in Figure 3.8 indicate that the presence of the 
technetium label is not affecting transport of the antibody out of the 
lung. This means that technetium is a suitable tracer to use in the 
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imaging experiments and that quantification of the re-distribution of an 
instilled technetium labelled antibody after intratracheal instillation will 
provide an accurate description of the in vivo pulmonary clearance of 
antibodies. 
3.4 Conclusions 
In summary the work detailed in this chapter indicates that the 
chemistry used to radiolabel the antibody with technetium is effective 
and reproducible. Additionally, the labelled antibody is stable in vivo 
over 24hrs and the presence of the technetium label does not interfere 
with antibody conformation or transport out of the lung. 
As the construct is stable and suitable for use as a tracer in the 
imaging experiment, work could move forward in imaging pulmonary 
antibody clearance and this is discussed in the next chapter. 
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CHAPTER 4: Imaging 
Clearance 
4. Overview 
Pulmonary Antibody 
This chapter details the results obtained from the imaging experiments 
designed to determine the rate and mechanism of antibody transport 
out of the lung. 
To determine the relative contributions of passive and active transport 
to the rate of antibody clearance, the clearance rates for whole IgG, 
antibody fragments and mutant IgG with different binding affinities for 
mFcRn are presented. The expression of mFcRn in the mouse lung is 
also investigated using immunohistochemical staining of paraffin 
embedded lung sections, in order to determine the extent of receptor 
availability for active transcytosis of intratracheally instilled IgG. 
4.1 Introduction 
This chapter details the results of the experiments designed to 
determine the rate and mechanism of pulmonary antibody clearance. 
Determination of the rate of clearance was achieved by imaging the 
distribution of an intratracheally instilled radiolabelled antibody, in vivo, 
over time using a combination of SPECT and CT imaging. In addition, 
the clearance of antibody fragments and the FN3 protein were 
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determined in the same manner to provide information regarding the 
extent of passive diffusion controlled processes on antibody clearance. 
As passive diffusion is inversely proportional to molecular weight it is 
expected that if passive diffusion is important in pulmonary antibody 
clearance then the increase in clearance rate of the IgG, Fab, scFv and 
FN3 plotted against molecular weight will be linear. The contribution of 
active transcytosis by mFcRn (see section 1.5 for more detail) to 
antibody clearance will be investigated using the mutant IgG produced 
in Chapter 2, with different binding affinities to mFcRn. If transcytosis 
by mFcRn is important in pulmonary antibody clearance then the 
clearance profiles of the IgG mutants would be expected to be 
significantly different, with the reduced and null binding mutants 
cleared more slowly than wild type IgG and with the improved binder 
perhaps being transported out of the lung faster than wild type. 
4.1.1 SPECT/CT imaging 
The imaging technique used to study the redistribution of the 
intratracheally instilled antibody, fragments and mutants in this work is 
a combination of CT and SPECT imaging. In brief, the combination of 
CT and SPECT imaging allows for the 3 dimensional localisation of 
radioactivity in vivo. The two images (CT and SPECT) are taken in the 
same animal in the exact same position, so that the images can be 
fused. The CT image is in essence a 3D X-ray of the animal and 
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provides anatomical information, which is overlaid with the 3D 
radioactivity map provided by the SPECT image. This results in an 
easily interpretable qualitative picture of the 3D distribution of the 
radiolabelled antibody within the animal, which can be quantified in 
terms of levels of radioactivity within a given region of interest. 
It is anticipated that the SPECT/CT images will provide the 
redistribution patterns for the radiolabelled proteins studied, both 
qualitatively in terms of which organs the proteins build up in over time 
and quantitatively in terms of the percentage of the originally instilled 
dose that remains in the lungs over the course of the experiment. 
Ultimately pulmonary retention profiles of the intratracheally instilled 
proteins will be generated over 24hrs. 
4.2 Materials and Methods 
4.2.1 Materials 
Technetium labelled WT IgG, Fab, scFv, FN3, IgG_H435A, 
IgG_V250Q and IgG_H435A_1253A were prepared as described in 
. Chapter 3. 
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4.2.2 Methods 
4.2.2.1 Statement of ethics for in vivo studies 
All in vivo experiments were performed in compliance with licences 
issued under the UK Animals (Scientific Procedures) Act 1986 
following local ethical review. 
4.2.2.2 SPECT/CT imaging protocol 
Female BALB/c mice, aged 8-12 weeks (n=6 per group), were 
purchased from Charles River UK Ltd (Margate, Kent, UK). The 
animals were housed in specific pathogen-free conditions in plastic 
cages with absorbent bedding material and maintained on a 12 hour 
daylight cycle. Food and water were provided ad libitum. The animals 
were acclimatised for a minimum of 7 days before commencement of 
studies. 
Animals were anaesthetized with 2.5% isoflurane in oxygen, 
suspended by the front incisors on a nose cone delivering 1.5% 
isoflurane in oxygen to maintain anaesthesia. Animals were 
intratracheally dosed with radiolabelled-antibody/fragment at 3 mg/kg 
and 20 MBq/mouse, by insertion of a dosing needle through the larynx 
and into the top of the trachea. Animals were allowed to recover and 
returned to their home cage. 
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At timepoints of 0, 2, 4, 8, 18 and 24 hours post dose, animals were 
terminally anaesthetized with ketamine (at 25 mg/kg) and 
medetomidine (at 1 mg/kg) delivered at a dose of 0.1 mLlkg via the 
intraperitoneal route. All imaging was performed on spontaneously 
breathing animals on a nanoSPECT/CT small animal imager (Bioscan 
Inc, Washington, DC, USA). CT acquisition was made at 45 kVp over 
360 continuous projections and the length of each CT scan was -3 
min. Respiratory gating was not employed in the study. Calibration of 
images for Hounsfield Unit (HU) scaling was performed using a water-
filled phantom once per day of imaging. SPECT acquisition was then 
performed using 24 projections each 20 s long. 
Following the completion of the SPECT scan, animals were sacrificed 
with an overdose of pentobarbitone sodium. The entire animal was 
placed in the well counter and total activity recorded. Blood was taken 
from the descending vena cava into pre-weighed EDTA anti-coagulant 
tubes, the sample was weighed and the total activity present assessed 
with the well counter. Blood samples were spun for 10 min at 5000 g 
and the plasma separated into fresh microfuge tubes. The lungs were 
also excised and total lung activity determined using the well counter. 
4.2.2.3 Image processing and fusion 
CT and SPECT images were processed with Amira 4.1 software 
(Visage Imaging, Andover, MA, USA). Both SPECT and CT images 
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were smoothed using a low pass 3D Gaussian filter. The skeleton was 
segmented in the CT image using an automatic threshold of 700 HU, 
this was manually inspected and altered to include all bone areas and 
excluded any non-bone areas. SPECT images were enlarged to the 
same dimensions as the corresponding CT image. Regions of interest 
were generated to include all activity above 50 units (arbitrary intensity 
units) either a) within the ribcage or b) outside of the ribcage. Activity 
within the rib cage was labelled as total lung activity. Finally, the 
skeleton from the CT image and 2 regions of interested from the 
SPECT image were viewed as, three dimensional isosurfaces. 
4.2.2.4 Histopathological measurement of mFcRn expression in 
healthy BALB/c mouse lung 
Two female BALB/c mice, aged 8 weeks (Harlan, UK), were 
euthanized with an overdose of sodium pentabarbitone. At necropsy, 
the trachea was cannulated and the lungs instilled with 10% neutral 
buffered formalin at a constant pressure of 25 cm H20. Once the lungs 
were fully distended, the trachea was tied off and the lungs removed 
from the thoracic cavity and post-fixed in 10 % neutral buffered formalin 
for 48 hours. Individual lobes were then trimmed and embedded in 
paraffin. 
Sections were cut at a thickness of 3 JJm, floated onto glass slides, 
dried overnight at 37°C and baked for 30 minutes at 60 °e. Sections 
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were dewaxed and rehydrated on a Leiko Autostainer XL and heat 
mediated antigen retrieval was performed by boiling the rehydrated 
sections in Low pH Antigen Unmasking Solution (Vector, H-3300) in a 
pressure cooker for 2 minutes. The pressure cooker was cooled and 
sections washed for 10 minutes in running tap water. Sections were 
then peroxidase blocked by immersion in 3 % hydrogen peroxide in 
methanol for 10 min. Sections were washed for 10 minutes in cold 
running tap water before loading onto a Dako Autostainer. 
Sections were blocked for 20 min in 2.5 % casein in DPBS, rinsed with 
DPBS-T, incubated for 60 minutes with goat anti-mFcRn primary 
antibody at 1 I-Ig/mL (R&D systems AF6673) or in DPBS-T for diluent 
controls. Sections were rinsed with DPBS-T, incubated with anti-goat 
ImmPress-HRP reagent (Vector, MP-7401) for 30 minutes, rinsed 
again with DPBS-T and incubated with DAB+ substrate/chromagen 
(Dako, K3468) for 5 mins. Sections were rinsed with MilliQ water and 
counterstained with Gills II Haematoxylin (Pioneer Research 
Chemicals, Colchester, Essex, UK) and Eosin Y (Acros Organics, 
Fisher Scientific, Loughborough, Leicestershire, UK) according to 
standard protocols. Slides were imaged on an Aperio digital slide 
scanner. 
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4.3 Results and Discussion 
4.3.1 Pulmonary clearance of a whole IgG 
Images of the redistribution of intratracheally instilled wild type IgG 
were generated at 0, 2, 4, 6, 18 or 24 hrs post dose. The CT scan from 
each animal was processed to generate a 3D representation of the 
skeleton, which was then overlaid with the radiation activity map from 
the SPECT image. The resulting fused image shows the distribution of 
the radiolabelled antibody throughout the body over time. 
Representative images for whole IgG redistribution at 0, 2, 4 and 24 
hrs post intratracheal instillation are shown in Figure 4.1. The images 
show qualitatively how the antibody redistributes. 
It can be seen from Figure 4.1 that high levels of radioactivity are 
present in the lungs up to 24 hrs post dose, with levels of lung activity 
appearing to decrease over the course of the experiment. Initially there 
is evidence of radiation within the trachea and larynx, it is expected that 
this has deposited during dosing as the dosing needle is put through 
the larynx and into the top of the trachea. The activity in the 
larynx/trachea is not detectable from 2 hours post dose, indicating that 
it is rapidly cleared, however it is not clear whether this activity is 
cleared by mucociliary clearance and swallowed or whether the 
antibody crosses the tracheal epithelium either by passive or active 
transport. 
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Figure 4.1 - Representative SPECT/CT images showing pulmonary retention of 
IgG at a) 0, b) 2, c) 4 and d) 24 hrs. Areas of lung activity are shaded green and 
areas of activity outside the lung shaded yellow. The images show decreasing 
levels of activity in the lung over 24 hrs, with activity visible within the bladder 
and intestines at some timepoints. 
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The later images also show a buildup of activity within the bladder and 
what appears to be the intestines. The activity in the bladder is not 
indicative of free technetium and is unlikely to be labelled antibody, as 
a 150 kDa protein would not pass through the healthy kidney. It is 
thought that this activity represents tagged breakdown products of the 
labelled antibody, where the radiolabel is attached to a sufficiently 
small protein fragment, which is capable of undergoing renal filtration 
(Le. less than 25 kDa). 
The activity within the intestines is more difficult to interpret, but could 
be indicative of mucociliary clearance. If mucociliary clearance was an 
important mechanism in antibody clearance it would be expected that 
later images would show activity moving from the trachea to the 
oesophagus stomach and then intestines, which is not observed in the 
images. No evidence was found for activity within the stomach in any 
animal from any time point, this lack of stomach activity is suggestive 
that mucociliary clearance is not occurring. 
Investigation of murine mucociliary clearance by scintigraphy 
suggested that clearance occurred in two phases, with tracheo-
bronchially deposited particles cleared over 24 hrs and alveolar 
deposited particles cleared over several months (Foster et aI., 2001). 
However, the particles studied by Foster were insoluble in water and 
the antibody solution instilled here is likely to rapidly diffuse through the 
mucus layer. From this we have concluded that liquid based 
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formulations of antibodies are unlikely to undergo significant 
mucociliary clearance. 
Importantly, there is no build up of activity observed within the stomach 
or thyroid, which is where free technetium would accumulate, This 
confirms that the radiolabelled antibody is stable in vivo over 24 hrs. 
The images in Figure 4.1 represent qualitatively the antibody 
redistribution after intratracheal instillation. However, by determining 
the activity present in the lung at each time point and relating this to the 
dose initially given to the animal it is possible to record the percentage 
of the instilled dose that remains in the lungs over the course of the 
experiment. This is represented graphically in Figure 4.2 and provides 
insight into the pulmonary retention rate of intratracheally instilled 
antibody. 
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Figure 4.2 - Graph showing the pulmonary retention of intratracheally instilled 
antibody over 24 hrs. Error bars are :t sem (n=6). 
Figure 4.2 shows the pulmonary retention of whole IgG over 24 hrs 
post intratracheal instillation. Initially there is a phase of comparatively 
rapid clearance up to 6 hours post dose, which is followed by a slower 
clearance phase up to 24 hours post dose. Non-linear regression, 
performed in GraphPad Prism 5, indicated that a biphasic exponential 
decay curve best described the data, the parameters for which can be 
seen in figure 4.3. 
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Parameter Best fit value 
YO 100 % (fixed) 
Plateau 55.37 ± 1.47 % 
%Fast 22.10 ± 7.13 % 
Kfast 6.24 ± 1.31 h-1 
Kslow 0.16 ± 0.033 h-1 
Half life (slow) 4.35 h 
Half life (fast) 0.11 h 
F Test p value 0.575 
Figure 4.3 - Table showing the best fit values for non-linear regression analysis 
(biphasic exponential decay model) for pulmonary clearance of WT whole 
mlgG. 
The data in figure 4.3 show that the pulmonary clearance of 
intratracheally instilled whole mlgG1 can be described by a two phase 
exponential decay model. The F test is a measure of whether the 
model is adequate to describe the data and compares the scatter 
between replicates at each timepoint to the distance between the point 
and the curve. A small p value indicates poor fit of the data to the 
model as the distance from the curve for each point is much greater 
than the distance between individual replicates. In this case the p value 
is above 0.05, which indicates adequate fit of the data to a biphasic 
exponential decay model. 
The data in figure 4.3 show that the pulmonary clearance of antibody 
can be described by an initial fast phase of clearance with a half life of 
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4.35 h, followed by a second slower phase of clearance with a half life 
of 0.11 h. Clearance reaches a plateau with 56 % of the originally 
instilled dose retained in the lungs after 24 hrs. Additional points post 
24 hrs would further help to define the plateau and further refine the 
model; however this is not possible using the SPECT/CT method 
employed as the natural decay of the technetium tracer makes time 
points post 24 hrs impossible to measure. 
4.3.2 Pulmonary clearance of antibody fragments and the FN3 
protein 
The clearance rates of inhaled antibody fragments from the lungs were 
then determined in order to investigate the importance of passive 
diffusion to the rate of antibody clearance. Images showing the 
redistribution of the instilled Fab and scFv fragments at 0,2,4 and 24 
hours post dose are shown in Figure 4.4. 
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Figure 4.4 - Representative SPECT/CT images showing pulmonary retention of 
A) Fab and B) scFv at i) 0, ii) 2, iii) 4 and iv) 24 hrs. Areas of lung activity are 
shaded green and areas of activity outside the lung shaded yellow. The images 
show decreasing levels of activity in the lung over 24 hrs, with activity visible 
within the bladder and intestines at some timepoints. 
The time courses for the antibody fragments in figure 4.4 show similar 
redistribution profiles to the original whole IgG. There is rapidly cleared 
tracheal deposition, decreasing lung activity over the course of the 
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experiment, but with detectable levels out to 24 hrs and some bladder 
and intestinal build-up of activity. Again there is no convincing evidence 
of mucociliary clearance with no gastric activity ever observed in any 
animal. 
The pulmonary retention profiles of the Fab and scFv fragments were 
determined as a percentage of the initially instilled dose and are 
expressed in Figure 4.5. 
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Figure 4.5 - Graph showing the pulmonary retention profiles of intratracheally 
instilled antibody, fragments and the FN3 protein over 24 hrs. Error bars are ± 
sem (n=6 per point). 
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Figure 4.5 shows that the pulmonary retention of whole IgG is 
significantly greater over 24 hrs than for either the Fab or scFv 
fragments. The fragments are initially cleared more rapidly than the 
whole IgG and, although the shapes of the curves are similar, the 
plateau reached for fragment retention is far lower than that for whole 
IgG. Specifically, it was determined that 54.4 ± 0.63 % of the total 
instilled dose of a whole monoclonal antibody remains in the lung over 
24 hrs, with Fab and scFv fragments cleared significantly quicker with 
28.7 ± 0.73 % and 34.9 ± 0.85 % respectively of the total instilled dose 
remaining in the lung at 24hrs. The pulmonary retention of the 11 kDa 
FN3 protein was also assessed with 21.0 ± 0.65 % remaining in the 
lungs after 24 hrs. 
Results were analysed separately at each time point using two tailed 
Student's unpaired t-tests; the retention for whole IgG was statistically 
significantly different from both fragments after 2 hours (p=0.008 vs. 
Fab and p=0.004 vs. scFv) and remained so over the whole 24 hr 
period (at 24hrs: p=0.002 vs. Fab and p=0.003 vs. scFv). The 
difference in clearance of the Fab and scFv fragments only reached 
statistical significance at 24 hrs post dose (p=0.022). These results 
indicate that the clearance rates of fragments at 50 and 28KDa are 
very similar using this detection method; however they can be 
distinguished from whole IgG. 
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The 11 kDa FN3 protein, the fibronectin III domain, which mimics an 
antibody fold, was used as a surrogate smaller antibody fragment than 
the scFv. The protein is not capable of binding antigen and its 
sequence is not related to the other proteins used in this work, 
inclusion of the data for this protein was simply to determine the 
pulmonary retention of a species smaller than an scFv. 
A lower pulmonary retention level at 24 hrs is expected for smaller 
fragments, in comparison to the larger fragments. However, the shape 
of the curve in Figure 4.5 for FN3 is indicative of a different clearance 
profile than the other proteins. The images in Figure 4.6a) show the 
redistribution of instilled labelled FN3 protein at 0,2,4 and 24 hrs post 
dose. Figure 4.6b) shows a rotated view of the 2 hr image, with two 
slices through the SPECT image at this time point, one showing activity 
within the kidney and the other activity within the lungs. 
The images in Figure 4.6 show the different redistribution pattern for 
the FN3 protein in comparison to the other proteins tested. There is 
significant renal filtration of labelled FN3, as evidenced by the very high 
levels of activity observed in the kidney from 2-4 hrs post dose. The 
images in Figure 4.6b) confirm renal filtration of the FN3 fragment, with 
the renal cortex highlighted in the SPEeT image. In addition the 
SPECT images of the lung shows good coverage of the periphery, with 
the instilled antibody covering the majority of the lung not just central 
regions. 
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Figure 4.6 - Representative SPECT/CT images showing: 
A) pulmonary retention of FN3 protein at i) 0, ii) 2, iii) 4 and iv) 24 hrs. Areas of 
lung activity are shaded green and areas of activity outside the lung shaded 
yellow. The images show decreasing levels of activity in the lung over 24 hrs, 
with activity visible within the bladder and intestines at some timepoints. In 
addition, there is activity visible in the kidneys between 2 and 4 hours post 
dose 
B) Rotated FN3 2 hr image with views from original SPECT scan showing 
activity in kidney and lungs. Black represents low activity and white represents 
high activity. 
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The pulmonary retention levels of each protein were plotted against 
molecular weight. If passive diffusive processes are important in 
determining the rate of antibody clearance from the lungs then a linear 
relationship would be expected between molecular weight and 
pulmonary retention, with larger molecules being more easily retained, 
according to Fick's law. The results of the comparison of pulmonary 
retention at 24hrs for each fragment are shown in Figure 4.7. 
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Figure 4.7 - Graph showing pulmonary retention of IgG, Fab, scFv and FN3 
protein 24 hrs post i.t instillation as a function of molecular weight. 
The results generally show the expected trend, with the larger proteins 
retained to greater extents than the smaller proteins, however the trend 
is not completely linear in appearance, appearing to plateau at larger 
molecular weights, with IgG cleared slightly quicker than a linear 
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relationship would suggest. Although there are only 4 data points the 
graph provides some indication that diffusion controlled processes are 
important in pulmonary antibody clearance and further implies that 
there could be a small, but significant role for active transport of IgG 
out of the lung. 
4.3.3 Pulmonary retention of mutant mlgG with differing binding 
affinities to mFcRn 
The pulmonary retention of the mutant versions of the whole IgG with 
differing binding affinities to mFcRn was determined. The results 
showing the percentage of the instilled dose remaining in the lungs 
over 24 hrs for each mutant is shown in Figure 4.8. 
Figure 4.8 shows that the pulmonary retention of each of the IgGs 
tested is very similar. Again there is initially comparatively rapid 
clearance which begins to plateau around 18-24hrs post dose. Two 
tailed, unpaired Student's t-tests were used to compare % pulmonary 
retention between each mutant separately at each time point, with no 
statistically significant differences reported below the p=O.05 level. This 
indicates that the clearance of each of the mutants, as determined 
here, is equal. This provides strong evidence that active transport by 
mFcRn is not important in pulmonary antibody clearance. 
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Figure 4.8 - Graph showing the pulmonary retention of intratraeheally instilled 
antibody and FeRn binding mutants over 24 hrs. Error bars are ± sem (n=6 per 
point). 
The result showing the mFcRn transport is not important in pulmonary 
antibody clearance is unexpected. Previous work by (Spiekermann, et 
aI., 2002) clearly demonstrated active pulmonary transport of 
erythropoetin (EPO) conjugated to an IgG Fc region. In the study 
EPO-Fc and EPO-Fc with binding to mFcRn ablated (Triple mutant 
including the H435A, 1243 and an additional H310A mutation) were 
delivered intranasally to female BALB/c mice and the reticulocyte 
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fraction (% red blood cells) determined after 4 days. The results 
showed an increase in % red blood cells of 15% for EPO-Fc and 10% 
for EPO-Fc_triple mutant, which was statistically significant. The result 
indicates that although passive diffusive processes are occurring for 
both molecules, there is a significant contribution to transport by active 
transcytosis. This was confirmed by co-administaration of EPO-Fc with 
an excess of IgG (competitively binds mFcRn) and chicken IgY (no 
binding to mFcRn), where IgG but not IgY reduced the % increase in 
red blood cells 4 days post dose. 
It was therefore expected in the current work to observe a role in 
antibody clearance for mFcRn. However there are two key differences 
between the studies that may explained the difference in results. 
Firstly, the EPO-Fc was detected by the biologic affect of EPO 4 days 
after the experiment, which is a measure of how much EPO-Fc has 
crossed the lung over 4 days and starts from an automatic 0 % value. 
In the study reported here, the pulmonary retention is calculated up to 
24 hrs post dose. The pulmonary retention starts from 100 % and 
drops over the course of the experiment. An increase from a zero 
baseline is more easily observed than a decrease from a 100 % 
. baseline, so this may result in the EPO study being more sensitive to 
small changes in the amount of EPO-Fc transferred. 
Secondly, the 4 day experimental length in the case of EPO allows 
more time for the antibody clearance to plateau and perhaps for the 
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clearance profiles of the WT and mutant version to diverge. In 
summary, the current research demonstrates that transcytosis of 
mFcRn is not important in antibody clearance from the lung over the 
first 24 hrs post dose. However, the research cannot rule out a 
contribution from active transcytosis which only becomes apparent at 
later time points, when passive diffusion is less dominant. 
4.3.4 Immunohistochemical analysis of the expression of 
mFcRn in the normal mouse lung 
In order to further examine the result showing no involvement of 
mFcRn transytosis in antibody clearance from the lung, 
immunohistochemical analysis of female BALB/c mouse lung tissue 
was carried out to test for the presence of mFcRn. The evidence for 
mFcRn expression in the lung in the literature is conflicting; several 
studies have found no evidence for mFcRn expression (Kuo & 
Avensen, 2011) (Akilesh, et aI., 2007), however two studies have 
shown expression of mFcRn at low levels, one in the epithelium 
(Spiekermann, et aI., 2002) and one throughout the entire lung 
(Sakagami, et aI., 2006). 
The histological analysis was performed as detailed in section 4.2.2.3 
and resulting images from the IHe are shown in Figure 4.9. 
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Figure 4.9 - Figure 4.9 - Image of mouse lung stained with anti-mFcRn antibody 
at x20 magnification. Brown areas represent mFcRn expression, visible in the 
epithelium, endothelium and on alveolar macrophages. 
In Figure 4.9 the brown colour represented mFcRn expression. The 
image covers a section of the lung containing alveoli, large airways and 
smaller blood vessels. mFcRn is known to be expressed at the 
endothelium and to be very strongly expressed on alveolar 
macrophages, it should be noted that FcRn expressed on 
macrophages would not contribute to transcytosis. Expression on 
alveolar macro phages was strong and there was some evidence for 
endothelial staining in blood vessels, however there was no evidence 
for epithelial staining for mFcRn in either the airways or alveoli. This 
result helps to explain the result observed with the mutant IgG, as there 
is no evidence for mFcRn expression in the lung and so the capacity of 
the mFcRn transcytosis pathway is expected to be low, due to the 
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absence or very low levels of receptor in the appropriate location to 
transcytose IgG. 
4.4 Conclusion 
This chapter has detailed the results obtained in the imaging studies 
designed to determine the rate and transport mechanisms for antibody 
transport out of the lung. It was determined that 54.4 ± 0.63 % of the 
total instilled dose of a whole monoclonal antibody remains in the lung 
over 24 hrs, with Fab and scFv fragments cleared significantly quicker 
with 28.7 ± 0.73 % and 34.9 ± 0.85 % respectively of the total instilled 
dose remaining in the lung at 24hrs. The pulmonary retention of the 11 
kOa FN3 protein was also assessed with 21.0 ± 0.65 % remaining in 
the lungs after 24 hrs. 
The results showed that passive diffusion controlled pathways are 
important in pulmonary antibody clearance and that, at least over the 
first 24 hrs, the contribution to clearance by transcytosis by mFcRn is 
not significant. This result was further clarified by the lack of evidence 
for mFcRn on the air facing surfaces of the lung as determined by IHe. 
Work now moved forward to investigate antibody clearance from the 
lung in a model of lung disease, which is detailed in the next chapter. 
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CHAPTER 5: Further Characterisation of and 
Investigation of Pulmonary Antibody Clearance in 
a Murine House Dust Mite Model of Asthma 
5. Overview 
This chapter details the work undertaken to further characterise the 
murine house dust mite (HOM) model of asthma and to determine 
whether pulmonary antibody clearance is altered in the diseased lung. 
Lung density changes following HOM exposure are assessed by CT 
imaging and related to cellular infiltration and pathology results. In 
addition the transport of IgG out of the HOM exposed lung is 
investigated, with the aim of determining how the rate of antibody 
clearance changes in the diseased lung. Finally the expression of the 
mFcRn receptor is determined in the HOM exposed lung in order to 
evaluate whether there will be any expected change in the contribution 
of active transcytosis to the pulmonary clearance of an intratracheally 
instilled antibody following HOM exposure. 
5.1 Introduction 
In practical terms, inhaled antibodies are unlikely to be delivered to the 
healthy lung in patients. The more promising targets for pulmonary 
delivery of biologics are within the lung and as such delivery is 
expected to be in the diseased lung. One possible disease which may 
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benefit from inhaled biological treatments is asthma and there is some 
ongoing research in this area. An inhaled synthetic analogue of 
vasoactive intestinal peptide has been shown to successfully induce 
bronchodilation in patients with stable asthma (Linden, et aI., 2003). In 
addition inhaled interleukin (IL) -4 receptor has been shown to stabilise 
asthma in patients upon the withdrawal of inhaled glucocorticosteroids 
(Borish, et aI., 1999). An anti-IL 13 antibody given intratracheally in 
mice has been shown to dose dependently attenuate the airway 
hyperresponsiveness caused by subsequent inhalation of IL-13 
(Blanchard, et aI., 2005). It was therefore decided to evaluate antibody 
clearance from the lung in an in vivo model of asthma, as a relevant 
diseased lung of interest. 
There are a number of in vivo models of asthma. The chronic murine 
house dust mite model of asthma has been shown to lead to severe 
and persistent airway inflammation, extensive airway eosinophilia, 
remodelling and a Th2-biased immune response, with increased airway 
resistance and bronchoconstrictor response to methacholine in house 
dust mite exposed animals. The inflammatory response can be 
reduced by treatment with corticosteroids and phosphodiesterase 4 
inhibitors, as is the case in human asthma (Nials & Uddin, 2008). 
In this work, further characterisation of the murine house dust mite 
(HOM) model will be undertaken to determine whether the changes in 
lung pathology can be monitored non-invasively with CT imaging. 
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Previous work has shown that CT imaging can be successfully 
employed to determine the density changes observed in the ovalbumin 
exposed lung, with an increase in density corresponding to an increase 
in pulmonary oedema and cellular infiltrate in the lungs. 
5.1.1 Affect of the diseased lung on antibody transport 
As the HOM exposed lung has been shown to be severely inflamed it is 
anticipated that the disruption to the epithelial surface will lead to 
greater epithelial permeability and an increase in the rate of antibody 
transport out of the lung by passive diffusion between the epithelial 
cells. There is currently no information available regarding the 
expression of mFcRn in the HOM exposed murine lung. This work will 
determine whether there is any up or down regulation of the mFcRn 
expression after HOM expose and will use the result to determine 
whether there is any change in the relative contribution to the 
pulmonary clearance of an inhaled antibody is expected. 
5.2 Materials and methods 
. 5.2.1.1 Statement of ethics for in vivo studies 
All in vivo experiments were performed in compliance with licences 
issued under the UK Animals (Scientific Procedures) Act 1986 
following local ethical review. 
143 
5.2.2 HOM dosing protocol used in CT imaging experiments 
Female BALB/c mice, aged 8-12 weeks (n=6 per group), were 
purchased from Charles River UK Ltd (Margate, Kent, UK). The 
animals were housed in specific pathogen-free conditions in plastic 
cages with absorbent bedding material and maintained on a 12 hour 
daylight cycle. Food and water were provided ad libitum. The animals 
were acclimatised for a minimum of 7 days before commencement of 
studies. 
Mice were exposed to house dust mite, HOM, according to an 
established chronic allergen exposure protocol. Under sterile 
conditions, extract of whole body purified and Iyophilised 
Dermatophagoides pteronyssinus house dust mites (Greer 
Laboratories, NC, USA) was re-suspended in sterile 0.9 % saline (Kabi 
Fresenius, UK) at a solution concentration of 500 J.Jg/mL total protein. 
The extract solution contained Oer p1 at 12.64 J.Jg/mL and bacterial 
endotoxin at 13 EU/ml. HOM aliquots were maintained until use at +4 
°C, with a single aliquot used each day and any remaining solution 
discarded once the aliquot had been opened. 
All mice receiving HOM were exposed to the allergen through a single 
daily 50 J.JL intranasal dose given under light isoflurane anaesthesia, on 
5 days each week, for up to 7 weeks. Control animals received a sham 
exposure of 50 J.JL sterile saline over the same time period using the 
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same method of administration. Over the final 2 weeks of HOM 
exposure, one group of animals was orally dosed with budesonide 
(Sigma-Aldrich, Poole, UK) at an initial dose of 3 mg/kg budesonide per 
day. Following significant weight loss, the dose was dropped to 
1 mg/kg after one day, for 2 weeks. All other animals (both HOM and 
saline control) received oral dose of saline. 
5.2.3 CT Imaging 
CT images were obtained once weekly from the week prior to exposure 
and 48 hours following the last HOM exposure in weeks 1, 2, 3,4, 5, 6 
and 7. Animals were anaesthetized with 2.5 % isoflurane in oxygen. All 
imaging was performed on spontaneously breathing animals on a 
nanoSPECT/CT small animal imager (Bioscan Inc, Washington, ~ C , ,
USA). CT acquisition was made at 45 kVp over 360 continuous 
projections and the length of each CT scan was -3 min. Respiratory 
gating was not employed in the study. Calibration of images for 
Hounsfield Unit (HU) scaling was performed using a water-filled 
phantom once per day of imaging. 
CT images were processed with Amira 4.1 software (Visage Imaging, 
Andover, MA, USA). Air filled lung volumes were selected using a 
computer-assisted volume selection from -1000 to -250 HU, which was 
visually inspected and altered as necessary to ensure inclusion of all 
lung areas and exclusion of any non-lung areas. 
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Three dimensional images were low pass filtered (Gaussian) and 
density histograms were produced with 150 bins describing a range 
from -1000 to 0 HU (7 HU/bin). Air filled lung volumes were 
determined by calculating the air volume in each bin based on the 
mean HU value, then summing the amount of air in each bin over the 
entire lung volume. 
Comparisons of lung density between treatment groups in each week 
were calculated using PROC MIXED in SAS v9.2, based on the modal 
lung density of each group. The model generated determined a 2 way 
analysis of variance, reflecting repeated measurements on the same 
animals each week, with pairwise contrasts of interest used to test the 
difference between treatment groups in each of the weeks. Results 
were deemed significant at the p=0.05Ievel. 
5.2.4 Assessment of antibody transport out of HDM exposed 
lung 
HOM sensitised and saline control mice, produced as described in 
section 5.2.2, were intratracheally dosed with whole IgG. Mice were 
anaesthetised with ketamine (80 mg/kg) and xylazine (8 mg/kg) given 
intraperitoneally (volume 5 mUkg). Mice were suspended on a 
dedicated PennCentury mouse dosing platform on a surgical table. The 
neck area was swabbed with 70 % ethanol and a small incision made 
with fine scissors above the trachea. Intratracheal administration of 50 
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IJL whole IgG solution at 1.5 mg/ml was given into the trachea through 
the muscle layer using a 1 mL syringe mUlti-stepper and a P30 needle. 
The skin incision was closed with VetBond cyanoacrylate adhesive and 
the mouse suspended for one minute on the dosing platform before 
being transferred to a warming cabinet until recovery (animals righted 
and ambulatory) or taken for necropsy. For post operative analgesia 
mice were given buprenorphine at 0.1 mg/kg. 
At time points 0, 2, 4, 6, 18 and 24hrs post dose animals were 
sacrificed with an overdose of pentobarbitone sodium. The lungs were 
lavaged with 3 x 0.3 mL cold OPBS. Total and differential cell counts 
were determined using a Sysmex automated haemocytometer and 
total mlgG1 content analysed by ELISA, as described in section 5.4.2. 
The large left lobe of the lungs was tied off and inflated with 1 mL 10% 
neutral buffered formalin, post fixed in 10 % NBF for 48 hours, before 
being embedded in paraffin. The paraffin embedded lung sections were 
analysed for mFcRn expression by IHe as described in section 4.2.2.3. 
5.2.5 mlgG1 ELISA 
Total mlgG1 in BAL and lung homogenate was determined by ELISA 
using a total mlgG1 ELISA kit (eBioscience, UK). Nunc maxisorb 96 
well plates were coated with 100 IJUwell anti-mouselgG1 capture 
antibody diluted 1 :250 in OPBS, sealed and incubated overnight at 4 
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CC. The plate was washed 2 x with 400 IJL DPBS-T then blocked with 
250 IJI/well 10% BSA in DPBS-T for 2 hours at room temperature. The 
plate was washed 2 x with 400 IJI/well DPBS-T and samples added at 
dilutions of 1 :5, 1 :50 and 1 :500. Standard was mlgG1 at 200 - 6.25 
ng/mL. Plates were then incubated with 50 IJUwell anti-mouse IgG-
HRP detection antibody at 1 :250 dilution in DPBS-T at room 
temperature for 3 hours. Plates were washed 4 x with 400 IJUwell 
DPBS-T and incubated with 100 IJUwell TMB for 15 minutes, when 100 
IJUwell 1 M sulphuric acid was added to each well. The plate was read 
at 450 nm. 
Results for HDM animals had background levels of increased mlgG1 in 
the HDM exposed mouse BALF (68.46 ± 21.39 IJg/ml) deducted from 
the ELISA result. 
5.2.6 Immunohistochemistry 
Lungs from HDM exposed and saline control animals were analysed 
for mFcRn expression as described in section 4.2.2.3. Additional 
sections were prepared as described in section 4.2.2.3 and stained 
with Gills II Haematoxylin (Pioneer Research Chemicals, Colchester, 
Essex, UK) and Eosin Y (Acros Organics, Fisher Scientific, 
Loughborough, Leicestershire, UK) according to standard protocols, to 
analyse disease progression. 
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5.3 Results 
5.3.1 Model development/characterisation 
5.3.1.1 Lung inflammatory cell influx 
Mice were exposed to HOM over the course of 7 weeks, the results of 
cell levels detectable in BALF showed that repeated intranasal delivery 
of house dust mite extract resulted in a robust and significant 
inflammatory response in the lungs, shown in Figure 5.1. When 
compared to saline control animals, HOM exposed animals showed a 
9-fold increase in total inflammatory cell numbers from 0.13 ± 0.02x106 
cells/mL to 1.17 ± 0.21 x106 cells/ml. After 2 weeks budesonide treated 
total cell counts compared the HOM group reduced approximately 3-
fold to 0.43 ± 0.12x1 06 cells/mL. 
Numbers of eosinophils were significantly increased in HOM treated 
animals with 0.8 ±0.05x104 cells/ml detected in saline control animals 
compared to 0.65±0.09x106 cells/ml in HOM treated animals. 
Budesonide treatment significantly reduced levels of eosinophils 
observed in HOM exposed animals to 0.16 ± 0.04 x105 cells/ml. 
Total BAL lymphocytes numbers increased from 0.89±0.16x104 
cells/ml in saline control animals to 0.22 ± 0.04x 1 06 cells/ml in HOM 
exposed animals. Budesonide treatment Significantly reduced 
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lymphocyte numbers in HOM treated animals to 0.42 ± 0.07x105 
cells/ml. 
Additionally, neutrophil numbers in saline treated animals increased 
from 0.2 ± 0.02x105 cells/ml to 0.22 ± 0.04x106 cells/ml in the HOM 
exposed group. Budesonide treatment had no effect on neutrophil 
numbers. Numbers of monocytes remained relatively unchanged with 
HOM exposure and were unaffected by budesonide treatment. 
These results are represented graphically in Figure 5.1, which shows 
that the increased total cell, eosinophil, lymphocyte and neutrophil 
levels in HOM exposed animals reach statistical significance at the 
p>0.005 level when compared to saline controls. Additionally, the 
changes in eosinophil numbers after HOM exposure reach statistical 
significance at the p>0.005 level when compared to HOM exposed 
animals which did not undergo budesonide treatment. Similar 
comparisons between HOM exposed and HOM exposed budesonide 
treated animals show reductions in total lymphocyte numbers reaching 
significance at the p>0.01 level. 
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Figure 5.1 - Graph showing cell numbers in BALF from saline control, HOM 
exposed and HOM exposed budesonide treated mice after 7 weeks HOM 
exposure and 2 week budesonide treatment. HOM exposure results in 
statistically significant increases in total cell numbers, Eos, Neuts and Lymphs. 
Numbers of Monos do not change. Budesonide treatment results in a 
statistically significant decrease in numbers of total cells, Eos and Lymphs. 
Analysis is with one tailed Student's unpaired t-test, * is p<O.05, ** is p<O.01 and 
'1'** is p<O.005. Error bars are ± sem (n=6 per group). 
5.3.1.2 CT Imaging results 
Animals were imaged once per week during HDM exposure. 
Representative CT slices for a saline control and a HDM exposed 
animal in weeks, 1, 5 and 7 are shown in figure 5.2, together with a 
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representative image of a HOM exposed budesonide treated animal in 
week 7. 
a) 
Vehicle 
Rib 
b) 
HOM 
Week 1 
Low density 
normal lung 
Week 5 
Spine 
Week 7 
No treatment 
BudesonJde 
treatment 
Figure 5.2 - Representative CT slices through mouse lungs exposed to a) 
saline or b) HOM over 7 weeks including c) an image comparing lungs of HOM 
exposed animals with or without budesonide treatment. Images show black as 
low density and white areas as higher density. Vehicle images showed no 
density changes over 7 weeks. HOM images showed a large area of increased 
density in week 5, which persists into week 7 if left untreated. Treatment with 
budesonide, results in a reduction in high density areas in week 7. 
The images in figure 5.2 show no changes in density within the lungs in 
an animal dosed with vehicle for 7 weeks, this is indicative of no 
development of lung pathology in this animal. However, representative 
slices of an animal dosed with HOM for 7 weeks show significant 
changes in lung structure, with increased high density areas clearly 
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visible after 5 weeks that persisted into week 7. Inflammation was 
generally observed to be peri-bronchial in nature. In contrast, animals 
dosed with HOM and treated with budesonide after week 5 showed 
some reversal of the HOM-induced pathology. 
The results observed in the images were quantified by calculation of 
the modal whole lung densities for each animal in each group. The 
results are shown in Figure 5.3 and show lung density for the vehicle 
group remaining constant over the 7 weeks. However, HOM exposed 
animals showed a marked increase in lung density over the course of 
the study, which became statistically significant at 2 weeks reaching a 
maximum at week 5 before reaching a plateau. Treatment with 
budesonide for 2 weeks reversed the increase in lung denSity to 
baseline levels with statistically significant differences in HOM exposed 
and HOM exposed budesonide treated groups in weeks 6 and 7 at 
p>O.01 and p>O.005 respectively. 
The CT data indicate that the lung density changes which occurred 
following HOM exposure are peri-bronchial in nature and are likely to 
be oedema or cellular inflammation. This conclusion is supported by 
the results seen in the BAL cell counts, which confirmed significant 
cellular infiltration in the airways and eosinophilic inflammation. The 
reversal of both the increase in density seen in the CT scans and 
increase in cell counts observed in BALF by steroid treatment again 
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point to increased cellular infiltration, although this does not rule out the 
presence of oedema. 
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Figure S.3 - Graph showing modal lung densities determined by CT imaging 
over 7 weeks for saline, HOM and HOM + budesonide exposed animals. HOM 
exposure results in increased lung density after 1 week, which persists over 7 
weeks if no treatment is given. Treatment with budesonide reverts lung density 
to baseline levels. * statistically significant changes in density between HOM 
and vehicle groups p<O.OS, # statistically significant change in lung density 
between HOM and HOM + budesonide groups, at ## = p<O.01 and ### = p<O.OOS. 
Error bars are ± sem (n=6 per group). 
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5.3.2 Histology 
5.3.2.1 Disease progression and mFcRn expression 
Representative images from the histological analysis of the saline 
control and HOM exposed lung can be seen in Figure 5.4. Images 
include areas of airway, vessel and alveoli. 
Histological examination showed that HOM exposure leads to both 
alveolitis and pneumonitis in the alveolar bed. There was also a 
marked perivascular cuffing, particularly of the systemic vessels and 
marked epithelial reaction, with an epithelial metaplasia typical of a 
reparative reaction within the mucosa. Giant multi-nuclear 
macrophages were also observed throughout the alveolar bed in HOM 
exposed animals, particularly close to the pleura. Additionally, there is 
very significant eosinophillia in the HOM exposed lung. These results 
are in line with other reports of the histology observed in HOM model. 
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Figure 5.4 - Images showing extent of inflammation in histological samples of 
a) saline and b) and c) HOM exposed lungs at x20 magnification. Image a) 
shows healthy lung. Image b) shows massive inflammation localised around 
airways and vessels. Image c) shows giant multinuclear macrophages in HOM 
exposed alveoli and inflammation around small vessels. 
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5.3.2.2 mFcRn expression in the HOM exposed lung 
mFcRn expression profiles in the normal lung were reported in section 
4.3.4 and in this section were compared to mFcRn expression in the 
saline challenged (representative of the normal lung) and HOM 
challenged lung. Representative images from this analysis can be seen 
in Figure 5.5. 
The images in Figure 5.5 show strong alveolar macrophage staining in 
both healthy and HOM exposed lung. Additionally, the same weak 
endothelial staining pattern is observed in both the healthy and 
inflamed lung. Epithelial staining is more difficult to compare in the two 
images. In the healthy lung there is no evidence for epithelial staining 
and in the inflamed lung analysis was complicated by an increase in 
mucus in the airways resulting in non-specific staining of the airways. 
In addition, there was strong non-specific staining observed in the HOM 
lung sections in areas of inflammation directly below larger airways. 
This is not FcRn expression and is possibly binding to collagen. 
Overall, however, there does not appear to be an increase in mFcRn 
expression in the HOM exposed lung, with no specific epithelial 
. staining observed. 
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Figure 5.5 - Images showing extent of mFcRn expression in histological 
samples of a) saline and b) HOM exposed lungs at x20 magnification. Brown 
colour indicates mFcRn expression or non-specific binding and in healthy lung 
(a) is visible on macrophages and epithelium. In HOM exposed lung (b) there is 
significant non-specific binding to mucus in the airways and in inflamed areas 
directly beneath the airways. 
As the level of mFcRn expression in the lung does not change with 
HOM exposure, transcytosis by mFcRn as a mechanism of antibody 
clearance from the lung is not expected to increase after HOM 
exposure. This indicates that any changes in antibody clearance in the 
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lung after HOM exposure are more likely to be occurring by changes in 
the rate of passive diffusion controlled processes. 
5.3.3 Antibody transport of out diseased lung 
The transport of intratracheally instilled IgG out of the HOM exposed 
lung was assessed by the change in mlgG1 levels detectable in BALF 
over 24 hrs. The results of BAL mlgG1 levels for both saline and HOM 
exposed animals are presented in Figure 5.6. The data show that 
clearance of IgG from HOM exposed lungs is more rapid than 
clearance from control lungs. 
Analysis of the results at each time point using the Mann Whitney test 
showed that there is a statistically significant decrease in BALF mlgG1 
levels after 2 hour, which lasts for 24 hrs. Results indicate that the 
damage induced by HOM to the mucosal surfaces of the lung leads to 
more rapid pulmonary clearance of macromolecules. This is the 
expected result and can be explained by an increase in epithelial 
permeability occurring due to an increase in passive diffusion 
controlled processes, probably paracellular diffusion between cells in 
the disrupted epithelium. 
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Figure 5.6 - Graph showing levels of antibody recoverable from the BALF over 
24hrs post intratracheal instillation in either HOM or saline control animals. 
Error bars are ± sem (n=6). 
5.4 Conclusion 
This penultimate chapter described the changes in X-ray anatomy and 
density of HOM exposed lungs using CT and related this to the 
pathology and cell infiltration in the HOM model. In addition the 
expression of mFcRn was found not to change following HOM 
exposure. Finally, the transport of antibody out of the HOM exposed 
lung was found to be more rapid that in the healthy lung, due to an 
increase in diffusion controlled transport out of the lung. 
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CHAPTER 6: Summary, Final Conclusions and 
Suggestions for Future Work 
6. Summary and final conclusions 
The work presented in this thesis has covered the set-up and validation 
of a SPECT/CT imaging based method to determine pulmonary 
antibody retention over 24 hrs. Pulmonary retention profiles were 
generated for a whole mlgG1, its Fab and scFv fragments, the FN3 
protein and a pool of three point mutated IgG with differing binding 
affinities to the mFcRn receptor. 
A SPECT/CT imaging method was successfully developed to 
investigate pulmonary antibody retention in vivo. The chemistry 
required to introduce the radiotracer to the antibody was proven to be 
simple and reproducible with no effect on antibody functionality. In 
addition, the radiolabelled antibody was proven to be stable in vivo 
over 24 hrs, which allowed for successful determination of the 
pulmonary retention profiles of intratracheally instilled proteins. In 
addition the SPECT/CT images showed no build up of activity in either 
the stomach or oesophagus, which strongly indicates that mucociliary 
clearance is not an important transport mechanism for intratracheally 
instilled antibody solutions in mice. 
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Comparison of the pulmonary retention rates for the whole IgG to those 
for the fragments and FN3 protein allowed determination of whether 
passive diffusion controlled processes were important in antibody 
clearance from the lung. This covers two separate diffusion controlled 
processes, paracellular transport and non-specific transcytosis. It was 
found that the pulmonary retention of whole antibody was significantly 
greater than for the smaller proteins. The retention profiles for the Fab 
and scFv fragments were very similar, but the FN3 protein was cleared 
more rapidly from the lung and also underwent significant levels of 
renal filtration. These results demonstrated a molecular weight 
dependence in pulmonary clearance, suggesting that diffusion 
controlled process were of greatest importance in determining the rate 
of antibody transport out of the lung. 
Comparison of the pulmonary retention of the WT mlgG1 with three 
mutants with differing binding affinities to mFcRn was completed to 
determine whether active transcytosis by mFcRn was an important 
mechanism for IgG transport out of the lungs. The results showed that 
the WT IgG and all mutants had very similar pulmonary retention 
profiles over 24 hrs indicating that, at least over the first 24 hrs, the 
capacity of the active transcytosis pathway to remove IgG from the 
lung is not high. Therefore over the first 24 hrs after dosing it appears 
that passive diffusion controlled pathways are responsible for the 
clearance of the majority of an intratracheally instilled antibody from the 
mouse lung. 
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In order to further explain this result the expression pattern of the 
mFcRn receptor was investigated immunohistochemically in the lung. 
There was no direct evidence for mFcRn expression in the pulmonary 
epithelium, although the results were difficult to interpret. 
The murine HOM model of asthma was used to investigate pulmonary 
antibody retention in the diseased lung. Additionally, the expression of 
the mFcRn receptor after exposure to HOM was investigated to 
determine whether active transcytosis would be expected to contribute 
to antibody clearance in the diseased lung. Finally, lung density 
changes on continuing exposure to HOM, were non invasively 
assessed by CT imaging. 
It was found that lung density increases progressively with increasing 
exposure to HOM. The density increase is a useful biomarker for the 
airway remodelling and inflammatory changes occurring in the lung and 
may represent an informative non-invasive method to assess disease 
progression. This could result in the need to use fewer animals in 
future HOM model studies, as fewer terminal procedures such as 
histological analysis could be required. 
In terms of antibody retention in the diseased lung, it was found that 
an intratracheally instilled antibody is less easily retained in the 
diseased lung than the normal lung. This was the expected result as it 
is known that mucosal barrier function is disrupted in the HOM model, 
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which was expected to lead to increased paracellular transport of 
antibody out of the lung. mFcRn expression appeared to be unchanged 
following HDM exposure, perhaps indicating that the increase in 
antibody transport out of the diseased lung was occurring through 
increased paracellular diffusion and not active transport by mFcRn. 
The major conclusion that can be drawn from this work is that 
antibodies are transported slowly from the normal lung at a rate of 
roughly half the initially deposited dose over 24 hrs and that the 
mechanism for this transport is diffusion controlled, at least over the 
first 24 hrs in the mouse. Furthermore the rate of antibody clearance 
from the diseased murine lung is higher than that in the normal lung 
and this increase appears to be driven by an increase in the rate of 
diffusion controlled clearance mechanisms. 
The results described above are indicative of retention of sufficient 
material to feasibly reach and maintain therapeutic levels of an inhaled 
antibody in the lung. The work also implies that for tailored delivery of 
biologics to the lung, pulmonary retention is increased in formats with 
high molecular weights. This impacts the possible formulation of 
biologics for inhalational delivery in that these results strongly suggest 
that the major factor influencing the pulmonary retention time for an 
inhaled protein is molecular weight. Therefore an antibody based 
therapy designed for inhalational treatment of asthma, cystic fibrosis or 
lung cancer may perform optimally as a full IgG rather than a fragment. 
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By comparing the results observed in this work to the literature, in 
particular regarding FcRn expression patterns in the lung, it is not clear 
how replicable these experiments would be in the human lung. More 
specifically, it appears that in the mouse, the active transcytosis 
pathway of IgG out of the lung by FcRn is not highly involved in 
antibody clearance; however there is convincing evidence for hFcRn 
expression in the human lung (Roopenian & Akilesh, 2007), so it is 
unclear whether this observation would hold true in human lungs. 
6.1 Suggestions for future work 
The work presented in this thesis provides a basis for the use of 
SPECTtCT imaging in understanding the pulmonary retention of 
antibodies in vivo over 24 hours. The inability to extend these studies 
beyond 24 hours, due to the radioactive decay of the technetium 
radiolabel, is one of the major limitations of this work. Analysis of the 
results has shown that it may be useful to extend the total time of the 
experiments beyond the 24 hr point, to obtain a better understanding of 
the terminal clearance mechanisms. This could be achieved by the use 
of a longer lived radiotracer than 99mTc, which has a 6 hour half life, for 
example 12310dine with a half life of 13 hours or 13110dine with an 8 day 
half life. In addition it would be possible to modify the protocol 
developed in this thesis to make use of PETtCT imaging and use 
longer lived PET traces such as 89Zr or 68Ga. 
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In more general terms there are a number of groups currently working 
on various aspects of the formulation of antibodies and other biologics 
for inhalational delivery. Work is ongoing to further elucidate factors 
influencing and mechanisms underpinning pulmonary drug dissolution, 
absorption transport and metabolism as well as to determine how to 
target specific lung regions and/or cell types. The continuation of this 
work is likely to result in the identification of a wider variety of biologics 
suitable for inhalational delivery and ultimately allow for the formulation 
of these molecules into effective inhaled medicines. 
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